



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ :		A2	(11) International Publication Number:	WO 00/29574
C12N 15/12, C07K 14/47, C12N 1/00, A61K 38/17, C07K 16/18, C12Q 1/68			(43) International Publication Date:	25 May 2000 (25.05.00)
(21) International Application Number:		PCT/US99/26234		
(22) International Filing Date:		4 November 1999 (04.11.99)		
(30) Priority Data:		09/195,292 18 November 1998 (18.11.98) US US 09/195,292 (CIP) Filed on 18 November 1998 (18.11.98)		
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).		
(71) Applicant (for all designated States except US):		INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).		
(72) Inventors; and				
(75) Inventors/Applicants (for US only):		WALKER, Michael, G. [CA/US]; Unit 80, 1050 Borregas Avenue, Sunnyvale, CA 94089 (US). VOLKMUTH, Wayne [US/US]; 783 Roble Avenue #1, Menlo Park, CA 94025 (US). KLINGLER, Tod, M. [US/US]; 28 Dover Court, San Carlos, CA 94070 (US).		
(74) Agents:		BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).		
(54) Title: INFLAMMATION-ASSOCIATED GENES				
(57) Abstract				
<p>The invention provides novel inflammation-associated genes and polypeptides encoded by those genes. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing diseases associated with inflammation.</p>				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Republic of Korea	RO	Romania		
CU	Cuba	LC	Kazakhstan	RU	Russian Federation		
CZ	Czech Republic	LI	Saint Lucia	SD	Sudan		
DE	Germany	LK	Liechtenstein	SE	Sweden		
DK	Denmark	LR	Sri Lanka	SG	Singapore		
EE	Estonia		Liberia				

INFLAMMATION-ASSOCIATED GENES

TECHNICAL FIELD

The invention relates to 11 inflammation-associated genes identified by their coexpression with known inflammation genes; to their corresponding polypeptides; and to the use of these biomolecules in diagnosis, prognosis, prevention and evaluation of therapies for diseases associated with inflammation.

BACKGROUND ART

Inflammation is the body's immediate, general response to wounding or infection by a pathogen. There are many complex phenomena that occur during an inflammation response. Initiation of the complement cascade, leukocyte recruitment, and leukocyte activation are three key events. In the complement cascade, a set of serum proteins, collectively called complement, non-specifically coat foreign matter. The coating proceeds in a cascade of steps using particular subsets of factors called complement components. The coated particles are then phagocytosed by macrophages or neutrophils recruited to the inflammation site. Leukocyte recruitment of monocytes and neutrophils is mediated by cytokines, which are proteins secreted by tissue at the inflammation site. Interleukin-8 (IL-8) is the primary chemoattractant cytokine responsible for recruitment in the initial stage of inflammation. In response to IL-8, monocytes and neutrophils are activated. An immediate response to activation is the expression of L-selectin and the integrins. L-selectin is a surface molecule that facilitates leukocyte binding (with relatively low affinity) to the endothelial cells lining blood vessels in the vicinity of the inflammation site. The integrins, also cell surface molecules, have stronger binding and mediate the actual extravasation of leukocytes from the blood vessel. Upon reaching the site of inflammation, receptors to the complement factors coating foreign particles are expressed on the leukocytes leading to phagocytosis and enzymatic degradation. Many genes that participate in and regulate the inflammation response are known, but many remain to be identified. Identification of currently unknown genes will provide new diagnostic and therapeutic targets for control of the inflammation response and treatment of inflammatory disorders.

The present invention provides new compositions that are useful for control of inflammation and for the diagnosis, prognosis, treatment, prevention, and evaluation of therapies for inflammatory disorders such as rheumatoid arthritis, Crohn's disease, multiple sclerosis, asthma and allergy. We have identified 11 novel inflammation-associated genes by their coexpression with known inflammation genes.

DISCLOSURE OF THE INVENTION

In one aspect, the invention provides for a substantially purified polynucleotide comprising a gene that is coexpressed with one or more known inflammation genes in a plurality of biological samples. Preferably, known inflammation genes are selected from the group consisting of CD16, L-selectin, Src-like adapter protein, IP-30, superoxidase homoenzyme subunits p67phox, p47phox, and p40phox, alpha-1-antitrypsin, Clq-A, 5-lipoxygenase activating protein, and SRC family tyrosine kinase. Preferred embodiments include (a) a polynucleotide sequence of SEQ ID NOs:1-11; (b) a polynucleotide sequence which encodes the polypeptide sequence 12, 13, 14, 15, 16, or 17; (c) a polynucleotide sequence having at least 70% identity to the polynucleotide sequence of (a) or (b); (d) a polynucleotide sequence which is complementary to the polynucleotide sequence of (a), (b), or (c); (e) a polynucleotide sequence comprising at least 10, preferably at least 18, sequential nucleotides of the polynucleotide sequence of (a), (b), (c), or (d); and (f) a polynucleotide which hybridizes under stringent conditions to the polynucleotide of (a), (b), (c), (d) or (e). Furthermore, the invention provides an expression vector comprising any of the above described polynucleotides and host cells comprising the expression vector. Still further, the invention provides a method for treating or preventing a disease or condition associated with the altered expression of a gene that is coexpressed with one or more known inflammation genes comprising administering to a subject in need a polynucleotide described above in an amount effective for treating or preventing said disease.

In a second aspect, the invention provides a substantially purified polypeptide comprising the gene product of a gene that is coexpressed with one or more known inflammation genes in a plurality of biological samples. The known inflammation gene may be selected from the group consisting of CD16, L-selectin, Src-like adapter protein, IP-30, superoxidase homoenzyme subunits p67phox, p47phox, and p40phox, alpha-1-antitrypsin, Clq-A, 5-lipoxygenase activating protein, and SRC family tyrosine kinase. Preferred embodiments are (a) the polypeptide sequence of SEQ ID NOs:12, 13, 14, 15, 16, or 17; (b) a polypeptide sequence having at least 85% identity to the polypeptide sequence of (a); and (c) a polypeptide sequence comprising at least 6 sequential amino acids of the polypeptide sequence of (a) or (b). Additionally, the invention provides antibodies that bind specifically to any of the above described polypeptides and a method for treating or preventing a disease or condition associated with the altered expression of a gene that is coexpressed with one or more known inflammation genes comprising administering to a subject in need such an antibody in an amount effective for treating or preventing said disease.

In another aspect, the invention provides a pharmaceutical composition comprising the polynucleotide or the polypeptide in conjunction with a suitable pharmaceutical carrier and a

method for treating or preventing a disease or condition associated with the altered expression of a gene that is coexpressed with one or more known inflammation genes comprising administering to a subject in need such a composition in an amount effective for treating or preventing said disease.

5 In a further aspect, the invention provides a ribozyme that cleaves a polynucleotide of the invention and a method for treating or preventing a disease or condition associated with the increased expression of a gene that is coexpressed with one or more known inflammation genes. The method comprises administering to a subject in need the ribozyme in an amount effective for treating or preventing the disease.

10 In yet a further aspect, the invention provides a method for diagnosing a disease or condition associated with the altered expression of a gene that is coexpressed with one or more known inflammation genes, wherein each known inflammation gene is selected from the group consisting of CD16, L-selectin, Src-like adapter protein, IP-30, superoxidase homoenzyme subunits p67phox, p47phox, and p40phox, alpha-1-antitrypsin, Clq-A, 5-lipoxygenase activating protein, and SRC family tyrosine kinase. The method comprises the steps of (a) providing the 15 sample comprising one of more of said coexpressed genes; (b) hybridizing the polynucleotide to said coexpressed genes under conditions effective to form one or more hybridization complexes; (c) detecting the hybridization complexes; and (d) comparing the levels of the hybridization complexes with the level of hybridization complexes in a nondiseased sample, wherein altered levels of one or more of the hybridization complexes in a diseased sample compared with the level 20 of hybridization complexes in a non-diseased sample correlates with the presence of the disease or condition.

Additionally, the invention provides antibodies that bind specifically to any of the above described polypeptides and a method for treating or preventing a disease or condition associated with the inflammation response.

25

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

The Sequence Listing provides exemplary inflammation-associated sequences including polynucleotide sequences, SEQ ID NOs:1-11, and polypeptide sequences, SEQ ID NOs:12-17. Each sequence is identified by a sequence identification number (SEQ ID NO) and by the Incyte Clone number from which the sequence was first identified.

30

DESCRIPTION OF THE INVENTION

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include the plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those

skilled in the art, and so forth.

DEFINITIONS

“NSEQ” refers generally to a polynucleotide sequence of the present invention including SEQ ID NOs:1-11. “PSEQ” refers generally to a polypeptide sequence of the present invention including SEQ ID NOs:12-17.

A “variant” refers to either a polynucleotide or a polypeptide whose sequence diverges from SEQ ID NOs:1-11 or SEQ ID NOs:12-17, respectively. Polynucleotide sequence divergence may result from mutational changes such as deletions, additions, and substitutions of one or more nucleotides; it may also occur because of differences in codon usage. Each of these types of changes may occur alone, or in combination, one or more times in a given sequence. Polypeptide variants include sequences that possess at least one structural or functional characteristic of SEQ ID NOs:12-17.

A “fragment” can refer to a nucleic acid sequence that is preferably at least 20 nucleic acids in length, more preferably 40 nucleic acids, and most preferably 60 nucleic acids in length, and encompasses, for example, fragments consisting of nucleic acids 1-50 of SEQ ID NOs:1-11. A “fragment” can also refer to polypeptide sequences which are preferably at least 5 to about 15 amino acids in length, most preferably at least 10 amino acids, and which retain some biological or immunological activity of, for example, a sequence selected from SEQ ID NOs:12-17.

“Gene” or “gene sequence” refers to the partial or complete coding sequence of a gene. The term also refers to 5' or 3' untranslated regions. The gene may be in a sense or antisense (complementary) orientation.

“Known inflammation gene” refers to a gene sequence which has been previously identified as useful in the diagnosis, treatment, prognosis, or prevention of diseases associated with inflammation. Typically, this means that the known gene is expressed at higher levels in tissue abundant in known inflammation transcripts when compared with other tissue.

“Inflammation-associated gene” refers to a gene sequence whose expression pattern is similar to that of the known inflammation genes and which are useful in the diagnosis, treatment, prognosis, or prevention of diseases associated with inflammation, particularly disorders such as rheumatoid arthritis, Crohn's disease, multiple sclerosis, asthma and allergy.

“Substantially purified” refers to a nucleic acid or an amino acid sequence that is removed from its natural environment and is isolated or separated, and is at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which it is naturally present.

THE INVENTION

The present invention encompasses a method for identifying biomolecules that are associated with a specific disease, regulatory pathway, subcellular compartment, cell type, tissue type, or species. In particular, the method identifies gene sequences useful in diagnosis, 5 prognosis, treatment, prevention, and evaluation of therapies for diseases associated with inflammation, particularly disorders such as rheumatoid arthritis, Crohn's disease, multiple sclerosis, asthma and allergy.

The method entails first identifying polynucleotides that are expressed in a plurality cDNA libraries. The identified polynucleotides include genes of known function, genes known to be 10 specifically expressed in a specific disease process, subcellular compartment, cell type, tissue type, or species. Additionally, the polynucleotides include genes of unknown function. The expression patterns of the known genes are then compared with those of the genes of unknown function to determine whether a specified coexpression probability threshold is met. Through this comparison, a subset of the polynucleotides having a high coexpression probability with the 15 known genes can be identified. The high coexpression probability correlates with a particular coexpression probability threshold which is less than 0.001, and more preferably less than 0.00001.

The polynucleotides originate from cDNA libraries derived from a variety of sources including, but not limited to, eukaryotes such as human, mouse, rat, dog, monkey, plant, and yeast 20 and prokaryotes such as bacteria and viruses. These polynucleotides can also be selected from a variety of sequence types including, but not limited to, expressed sequence tags (ESTs), assembled polynucleotide sequences, full length gene coding regions, introns, regulatory sequences, 5' untranslated regions, and 3' untranslated regions. To have statistically significant analytical results, the polynucleotides need to be expressed in at least three cDNA libraries.

25 The cDNA libraries used in the coexpression analysis of the present invention can be obtained from blood vessels, heart, blood cells, cultured cells, connective tissue, epithelium, islets of Langerhans, neurons, phagocytes, biliary tract, esophagus, gastrointestinal system, liver, pancreas, fetus, placenta, chromaffin system, endocrine glands, ovary, uterus, penis, prostate, seminal vesicles, testis, bone marrow, immune system, cartilage, muscles, skeleton, central 30 nervous system, ganglia, neuroglia, neurosecretory system, peripheral nervous system, bronchus, larynx, lung, nose, pleurus, ear, eye, mouth, pharynx, exocrine glands, bladder, kidney, ureter, and the like. The number of cDNA libraries selected can range from as few as 3 to greater than 10,000. Preferably, the number of the cDNA libraries is greater than 500.

In a preferred embodiment, gene sequences are assembled to reflect related sequences,

such as assembled sequence fragments derived from a single transcript. Assembly of the polynucleotide sequences can be performed using sequences of various types including, but not limited to, ESTs, extensions, or shotgun sequences. In a most preferred embodiment, the polynucleotide sequences are derived from human sequences that have been assembled using the 5 algorithm disclosed in "Database and System for Storing, Comparing and Displaying Related Biomolecular Sequence Information", Lincoln et al., Serial No:60/079,469, filed March 26, 1998, incorporated herein by reference.

Experimentally, differential expression of the polynucleotides can be evaluated by methods including, but not limited to, differential display by spatial immobilization or by gel 10 electrophoresis, genome mismatch scanning, representational difference analysis, and transcript imaging. Additionally, differential expression can be assessed by microarray technology. These methods may be used alone or in combination.

Known inflammation genes can be selected based on the use of the genes as diagnostic or prognostic markers or as therapeutic targets for diseases associated with inflammation. 15 Preferably, the known inflammation genes include CD16, L-selectin, Src-like adapter protein (SLAP), IP-30, superoxidase homoenzyme subunits (p67phox, p47phox, and p40phox), alpha-1-antitrypsin (AAT), Clq-A, 5-lipoxygenase activating protein (FLAP), and SRC family tyrosine kinase (HCK), and the like.

The procedure for identifying novel genes that exhibit a statistically significant 20 coexpression pattern with known inflammation genes is as follows. First, the presence or absence of a gene sequence in a cDNA library is defined: a gene is present in a cDNA library when at least one cDNA fragment corresponding to that gene is detected in a cDNA sample taken from the library, and a gene is absent from a library when no corresponding cDNA fragment is detected in the sample.

Second, the significance of gene coexpression is evaluated using a probability method to 25 measure a due-to-chance probability of the coexpression. The probability method can be the Fisher exact test, the chi-squared test, or the kappa test. These tests and examples of their applications are well known in the art and can be found in standard statistics texts (Agresti (1990) Categorical Data Analysis, John Wiley & Sons, New York NY; Rice (1988) Mathematical

30 Statistics and Data Analysis, Duxbury Press, Pacific Grove CA). A Bonferroni correction (Rice, supra, page 384) can also be applied in combination with one of the probability methods for correcting statistical results of one gene versus multiple other genes. In a preferred embodiment, the due-to-chance probability is measured by a Fisher exact test, and the threshold of the due-to-chance probability is set to less than 0.001, more preferably less than 0.00001.

To determine whether two genes, A and B, have similar coexpression patterns, occurrence data vectors can be generated as illustrated in Table 1, wherein a gene's presence is indicated by a one and its absence by a zero. A zero indicates that the gene did not occur in the library, and a one indicates that it occurred at least once.

5

Table 1. Occurrence data for genes A and B

	Library 1	Library 2	Library 3	...	Library N
gene A	1	1	0	...	0
gene B	1	0	1	...	0

10 For a given pair of genes, the occurrence data in Table 1 can be summarized in a 2 x 2 contingency table.

Table 2. Contingency table for co-occurrences of genes A and B

15

	Gene A present	Gene A absent	Total
Gene B present	8	2	10
Gene B absent	2	18	20
Total	10	20	30

Table 2 presents co-occurrence data for gene A and gene B in a total of 30 libraries. Both gene A and gene B occur 10 times in the libraries. Table 2 summarizes and presents 1) the number of times gene A and B are both present in a library, 2) the number of times gene A and B are both absent in a library, 3) the number of times gene A is present while gene B is absent, and 4) the number of times gene B is present while gene A is absent. The upper left entry is the number of times the two genes co-occur in a library, and the middle right entry is the number of times neither gene occurs in a library. The off diagonal entries are the number of times one gene occurs while the other does not. Both A and B are present eight times and absent 18 times, gene A is present while gene B is absent two times, and gene B is present while gene A is absent two times. The probability ("p-value") that the above association occurs due to chance as calculated using a Fisher exact test is 0.0003. Associations are generally considered significant if a p-value is less than 0.01 (Agresti, *supra*; Rice, *supra*).

20 This method of estimating the probability for coexpression of two genes makes several assumptions. The method assumes that the libraries are independent and are identically sampled. However, in practical situations, the selected cDNA libraries are not entirely independent because more than one library may be obtained from a single patient or tissue, and they are not entirely

identically sampled because different numbers of cDNA's may be sequenced from each library (typically ranging from 5,000 to 10,000 cDNA's per library). In addition, because a Fisher exact coexpression probability is calculated for each gene versus 41,419 other genes, a Bonferroni correction for multiple statistical tests is necessary.

5 Using the method of the present invention, we have identified 11 novel genes that exhibit strong association, or coexpression, with known genes that are inflammation-specific. These known inflammation genes include CD16, L-selectin, Src-like adapter protein (SLAP), IP-30, superoxidase homoenzyme subunits (p67phox, p47phox, and p40phox), alpha-1-antitrypsin (AAT), Clq-A, 5-lipoxygenase activating protein (FLAP), and SRC family tyrosine kinase (HCK).

10 The results presented in Table 5 show that the expression of the 11 novel genes have direct or indirect association with the expression of known inflammation genes. Therefore, the novel genes can potentially be used in diagnosis, treatment, prognosis, or prevention of diseases associated with inflammation, or in the evaluation of therapies for diseases associated with inflammation. Further, the gene products of the 11 novel genes are potential therapeutic proteins

15 and targets of therapeutics against diseases associated with inflammation.

Therefore, in one embodiment, the present invention encompasses a polynucleotide sequence comprising the sequence of SEQ ID Nos:1-11. These 11 polynucleotides are shown by the method of the present invention to have strong coexpression association with known inflammation genes and with each other. The invention also encompasses a variant of the 20 polynucleotide sequence, its complement, or 18 consecutive nucleotides of a sequence provided in the above described sequences. Variant polynucleotide sequences typically have at least about 70%, more preferably at least about 85%, and most preferably at least about 95% polynucleotide sequence identity to NSEQ. One preferred method for identifying variants entails using NSEQ and/or PSEQ sequences to search against the GenBank primate (pri), rodent (rod), and 25 mammalian (mam), vertebrate (vrtp), and eukaryote (eukp) databases, SwissProt, BLOCKS (Bairoch et al. (1997) Nucleic Acids Res 25:217-221), PFAM, and other databases that contain previously identified and annotated motifs, sequences, and gene functions. Methods that search for primary sequence patterns with secondary structure gap penalties (Smith (1992) Prot Eng 5:35-51) as well as algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul (1993) J 30 Mol Evol 36:290-300; and Altschul et al. (1990) J Mol Biol 215:403-410), BLOCKS (Henikoff and Henikoff (1991) Nucleic Acids Res 19:6565-6572), Hidden Markov Models (HMM; Eddy (1996) Cur Opin Str Biol 6:361-365; and Sonnhammer et al. (1997) Proteins 28:405-420), and the like, can be used to manipulate and analyze nucleotide and amino acid sequences. These databases, algorithms and other methods are well known in the art and are described in Ausubel et

al. (1997; Short Protocols in Molecular Biology, John Wiley & Sons. New York NY) and in Meyers (1995; Molecular Biology and Biotechnology, Wiley VCH. New York NY).

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to SEQ ID NOs:1-11, and fragments thereof under stringent conditions. Stringent conditions can be defined by salt concentration, temperature, and other chemicals and conditions well known in the art. In particular, stringency can be increased by reducing the concentration of salt, or raising the hybridization temperature.

For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and most preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, more preferably of at least about 37°C, and most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent or solvent, and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Additional variations on these conditions will be readily apparent to those skilled in the art (Wahl and Berger (1987) Methods Enzymol 152:399-407; Kimmel (1987) Methods Enzymol 152:507-511; Ausubel, supra; and Sambrook et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY).

NSEQ or the polynucleotide sequences encoding PSEQ can be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. (See, e.g., Dieffenbach and Dveksler (1995) PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview NY; Sarkar (1993) PCR Methods Applic 2:318-322; Triglia et al. (1988) Nucleic Acids Res 16:8186; Lagerstrom et al. (1991) PCR Methods Applic 1:111-119; and Parker et al. (1991) Nucleic Acids Res 19:3055-306). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto, CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 18 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

In another aspect of the invention, NSEQ or the polynucleotide sequences encoding PSEQ can be cloned in recombinant DNA molecules that direct expression of PSEQ or the polypeptides encoded by NSEQ, or structural or functional fragments thereof, in appropriate host cells. Due to

the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express the polypeptides of PSEQ or the polypeptides encoded by NSEQ. The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter the 5 nucleotide sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter 10 glycosylation patterns, change codon preference, produce splice variants, and so forth.

In order to express a biologically active polypeptide encoded by NSEQ or the polynucleotide sequences encoding PSEQ, or derivatives thereof, may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These 15 elements include regulatory sequences such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and NSEQ or polynucleotide sequences encoding PSEQ. Methods which are well known to those skilled in the art may be used to construct expression vectors containing NSEQ or polynucleotide sequences encoding PSEQ and appropriate transcriptional and translational control elements. These methods include in vitro recombinant 20 DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, supra and Ausubel, supra.)

A variety of expression vector/host cell systems may be utilized to contain and express NSEQ or polynucleotide sequences encoding PSEQ. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid 25 DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (baculovirus); plant cell systems transformed with viral expression vectors, cauliflower mosaic virus (CaMV) or tobacco mosaic virus (TMV), or with bacterial expression vectors (Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed. For long term production of recombinant proteins in 30 mammalian systems, stable expression of a polypeptide encoded by NSEQ in cell lines is preferred. For example, NSEQ or sequences encoding PSEQ can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector.

In general, host cells that contain NSEQ and that express PSEQ may be identified by a

variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences. Immunological methods for 5 detecting and measuring the expression of PSEQ using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS).

Host cells transformed with NSEQ or polynucleotide sequences encoding PSEQ may be 10 cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides of NSEQ or polynucleotides encoding PSEQ may be designed to contain signal sequences which direct secretion of PSEQ through a prokaryotic or 15 eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" 20 form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC, Manassas, MD) and may be chosen to ensure the correct modification and processing of the foreign protein.

25 In another embodiment of the invention, natural, modified, or recombinant NSEQ or nucleic acid sequences encoding PSEQ are ligated to a heterologous sequence resulting in translation of a fusion protein containing heterologous protein moieties in any of the aforementioned host systems. Such heterologous protein moieties facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited 30 to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, hemagglutinin (HA) and monoclonal antibody epitopes.

In another embodiment, NSEQ or sequences encoding PSEQ are synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers et al. (1980) Nucleic

Acids Symp Ser (7)215-223; Horn et al. (1980) Nucleic Acids Symp Ser (7)225-232; and Ausubel, *supra*). Alternatively, PSEQ or a polypeptide sequence encoded by NSEQ itself, or a fragment thereof, may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge et al. (1995) Science

5 269:202-204). Automated synthesis may be achieved using the ABI 431A Peptide synthesizer (PE Biosystems, Foster City CA). Additionally, PSEQ or the amino acid sequence encoded by NSEQ, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a polypeptide variant.

10 In another embodiment, the invention entails a substantially purified polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:12-17 or fragments thereof.

DIAGNOSTICS and THERAPEUTICS

15 The sequences of the these genes can be used in diagnosis, prognosis, treatment, prevention, and evaluation of therapies for diseases associated with inflammation, particularly disorders such as rheumatoid arthritis, Crohn's disease, multiple sclerosis, asthma, and allergy.

20 In one preferred embodiment, the polynucleotide sequences of NSEQ or the polynucleotides encoding PSEQ are used for diagnostic purposes to determine the absence, presence, and excess expression of PSEQ. The polynucleotides may be at least 18 nucleotides long, complementary RNA and DNA molecules, branched nucleic acids, and peptide nucleic acids (PNAs). Alternatively, the polynucleotides are used to detect and quantitate gene expression in samples in which expression of NSEQ or the polypeptides encoded by NSEQ are correlated with disease. Additionally, NSEQ or the polynucleotides encoding PSEQ can be used to detect genetic polymorphisms associated with a disease. These polymorphisms may be detected at the transcript cDNA or genomic level.

25 The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low), will determine whether the probe identifies only naturally occurring sequences encoding PSEQ, allelic variants, or related sequences.

30 Probes may also be used for the detection of related sequences, and should preferably have at least 70% sequence identity to any of the NSEQ or PSEQ-encoding sequences.

Means for producing specific hybridization probes for DNAs encoding PSEQ include the cloning of NSEQ or polynucleotide sequences encoding PSEQ into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to

synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, by fluorescent labels, and the like. The polynucleotide sequences encoding PSEQ may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; and in microarrays utilizing fluids or tissues from patients to detect altered PSEQ expression. Such qualitative or quantitative methods are well known in the art.

NSEQ or the nucleotide sequences encoding PSEQ can be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed, and the signal is quantitated and compared with a standard value, typically, derived from a non-diseased sample. If the amount of signal in the patient sample is altered in comparison to the standard value then the presence of altered levels of nucleotide sequences of NSEQ or those encoding PSEQ in the sample indicates the presence of the associated disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

Once the presence of a disease is established and a treatment protocol is initiated, hybridization or amplification assays can be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in a healthy subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

The polynucleotides may be used for the diagnosis of a variety of diseases associated with inflammation, particularly for diseases including, but not limited to, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus,

systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma.

The polynucleotides may also be used as targets in a microarray. The microarray can be
5 used to monitor the expression level of large numbers of genes simultaneously and to identify splice variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disease, to diagnose a disease, and to develop and monitor the activities of therapeutic agents.

In yet another alternative, polynucleotides may be used to generate hybridization probes
10 useful in mapping the naturally occurring genomic sequence. Fluorescent *in situ* hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich et al. (1995) In: Meyers, *supra*). Microarrays may be used to detect genetic diversity at the genome level.

In another embodiment, antibodies which specifically bind PSEQ may be used for the
15 diagnosis of diseases characterized by the over-or-underexpression of PSEQ or polypeptides encoded by NSEQ. A variety of protocols for measuring PSEQ, or the polypeptides encoded by NSEQ, including ELISAs, RIAs, and FACS are well known in the art and provide a basis for diagnosing altered or abnormal levels of the expression of PSEQ or the polypeptides encoded by NSEQ. Standard values for PSEQ expression are established by combining body fluids or cell
20 extracts taken from healthy subjects, preferably human, with antibody to PSEQ or a polypeptide encoded by NSEQ under conditions suitable for complex formation. The amount of complex formation may be quantitated by various methods, preferably by photometric means. Quantities of PSEQ or the polypeptides encoded by NSEQ expressed in disease samples from, for example, biopsied tissues are compared with the standard values. Deviation between standard and subject
25 values establishes the parameters for diagnosing or monitoring disease. Alternatively, one may use competitive drug screening assays in which neutralizing antibodies capable of binding PSEQ or the polypeptides encoded by NSEQ specifically compete with a test compound for binding the polypeptides. Antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PSEQ or the polypeptides encoded by NSEQ.

30 In another aspect, the polynucleotides and polypeptides of the present invention can be employed for treatment or the monitoring of therapeutic treatments for cancers. The polynucleotides of NSEQ or those encoding PSEQ, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotides of NSEQ or those encoding PSEQ may be used in situations in which it would be desirable to block the

transcription or translation of the mRNA.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art 5 can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding PSEQ. (See, e.g., Sambrook, supra; and Ausubel, supra.)

Genes having polynucleotide sequences of NSEQ or those encoding PSEQ can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or a fragment thereof, encoding PSEQ. Such constructs may be used to introduce 10 untranslatable sense or antisense sequences into a cell. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent 15 therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee et al. (1994) In: Huber and Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.)

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the cleavage of mRNA and decrease the levels of particular mRNAs, such as those comprising the polynucleotide 20 sequences of the invention. (See, e.g. Rossi, (1994) Current Biology 4:469-471.) Ribozymes may cleave mRNA at specific cleavage sites. Alternatively, ribozymes may cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The construction and production of ribozymes is well known in the art and is described in Meyers 25 (supra).

RNA molecules may be modified to increase intracellular stability and half-life. Possible 30 modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiester linkages within the backbone of the molecule. Alternatively, nontraditional bases such as inosine, queosine, and wybutoxine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous 35 endonucleases may be included.

Alternatively, the polynucleotides of the invention may be integrated into a genome by somatic or germ cell gene therapy. Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors

may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman et al. (1997) *Nature Biotechnol* 15:462-466.)

5 Additionally, endogenous polynucleotide expression may be inactivated using homologous recombination methods which insert an inactive gene sequence at the target sequence location. (See, e.g. Thomas and Capecchi (1987) *Cell* 51:503-512.)

Further, an antagonist or antibody of a polypeptide of PSEQ or encoded by NSEQ may be administered to a subject to treat or prevent a cancer associated with increased expression or 10 activity of PSEQ. An antibody which specifically binds the polypeptide may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express the the polypeptide.

Antibodies to PSEQ may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single 15 chain antibodies, Fab fragments, and fragments produced by a Fab expression library.

Neutralizing antibodies, those which inhibit dimer formation, are especially preferred for therapeutic use. Monoclonal antibodies to PSEQ may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, 20 and the EBV-hybridoma technique. In addition, techniques developed for the production of chimeric antibodies can be used. (See, e.g., Meyers, *supra*.) Alternatively, techniques described for the production of single chain antibodies may be employed. Antibody fragments which contain specific binding sites for PSEQ or the polypeptide sequences encoded by NSEQ may also be generated.

25 Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art.

Yet further, an agonist of PSEQ or that encoded by NSEQ may be administered to a 30 subject to treat or prevent a cancer associated with decreased expression or activity of the polypeptide.

An additional aspect of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of

polypeptides of PSEQ or those encoded by NSEQ, antibodies to the polypeptides, and mimetics, agonists, antagonists, or inhibitors of the polypeptides. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, 5 saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, 10 enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found 15 in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes 20 for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example, polypeptides of PSEQ or those encoded by NSEQ, or fragments thereof, antibodies of the polypeptides, and agonists, antagonists or inhibitors of the polypeptides, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard 25 pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED₅₀ (the dose therapeutically effective in 50% of the population) or LD₅₀ (the dose lethal to 50% of the population) statistics.

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, 30 monkeys, and most preferably, humans.

EXAMPLES

It is understood that this invention is not limited to the particular methodology, protocols, and reagents described, as these may vary. It is also understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope

of the present invention which will be limited only by the appended claims. The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

I cDNA Library Construction

5 The cDNA library, OVARTUT05, was selected as an example to demonstrate the construction of the cDNA libraries from which the sequences used to identify genes associated with inflammation were derived. The OVARTUT05 library was constructed from tumorous ovary tissue obtained from a 62 year-old Caucasian female. Pathology indicated a grade 4 endometrioid carcinoma with extensive squamous differentiation forming a solid mass in the right ovary. The 10 cervix showed mild chronic cervicitis, and the posterior uterine serosa showed focal endometriosis. Prior pathology indicated weakly proliferative endometrium with excessive stromal breakdown in the uterus and a mild chronic cervicitis with prominent nabothian cyst in the cervix.

15 The frozen tissue was homogenized and lysed using a POLYTRON homogenizer (PT-3000; Brinkmann Instruments, Westbury NY) in guanidinium isothiocyanate solution. The lysate was centrifuged over a 5.7 M CsCl cushion using an SW28 rotor in a L8-70M ultracentrifuge (Beckman Coulter, Fullerton CA) for 18 hours at 25,000 rpm at ambient temperature. The RNA was extracted with acid phenol, pH 4.7, precipitated using 0.3 M sodium acetate and 2.5 volumes of ethanol, resuspended in RNase-free water, and treated with DNase at 20 37°C. The RNA extraction was repeated with acid phenol, pH 4.7 and precipitated with sodium acetate and ethanol as before. The mRNA was then isolated using the OLIGOTEX kit (Qiagen, Chatsworth CA) and used to construct the cDNA library.

25 The mRNA was handled according to the recommended protocols in the SUPERSCRIPT Plasmid system (Life Technologies, Rockville MD). The cDNAs were fractionated on a SEPHAROSE CL4B column (Amersham Pharmacia Biotech, Piscataway NJ), and those cDNAs exceeding 400 bp were ligated into pINCY 1 plasmid (Incyte Pharmaceuticals, Palo Alto CA). The plasmid was subsequently transformed into DH5α competent cells (Life Technologies).

II Isolation and Sequencing of cDNA Clones

30 Plasmid DNA was released from the cells and purified using the REAL Prep 96 Plasmid kit (Qiagen). This kit enabled the simultaneous purification of 96 samples in a 96-well block using multi-channel reagent dispensers. The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Terrific Broth (Life Technologies) with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) after inoculation, the cultures were incubated for 19 hours and at the end of incubation, the cells were lysed with 0.3 ml of lysis

buffer; and 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml of distilled water. After the last step in the protocol, samples were transferred to a 96-well block for storage at 4° C.

The cDNAs were prepared using a MICROLAB 2200 (Hamilton, Reno NV) in combination with DNA ENGINE thermal cyclers (PTC200; MJ Research, Watertown MA) and sequenced by the method of Sanger et al. (1975, *J Mol Biol* 94:441f) using ABI PRISM 377 DNA Sequencing systems (PE Biosystems).

III Selection, Assembly, and Characterization of Sequences

The sequences used for coexpression analysis were assembled from EST sequences, 5' and 3' longread sequences, and full length coding sequences. Selected assembled sequences were expressed in at least three cDNA libraries.

The assembly process is described as follows. EST sequence chromatograms were processed and verified. Quality scores were obtained using PHRED (Ewing et al. (1998) *Genome Res* 8:175-185; Ewing and Green (1998) *Genome Res* 8:186-194). Then the edited sequences were loaded into a relational database management system (RDBMS). The EST sequences were clustered into an initial set of bins using BLAST with a product score of 50. All clusters of two or more sequences were created as bins. The overlapping sequences represented in a bin correspond to the sequence of a transcribed gene.

Assembly of the component sequences within each bin was performed using a modification of PHRAP, a publicly available program for assembling DNA fragments (Green, University of Washington, Seattle WA). Bins that showed 82% identity from a local pair-wise alignment between any of the consensus sequences were merged.

Bins were annotated by screening the consensus sequence in each bin against public databases, such as GBpri and GenPept from NCBI. The annotation process involved a FASTn screen against the GBpri database in GenBank. Those hits with a percent identity of greater than or equal to 70% and an alignment length of greater than or equal to 100 base pairs were recorded as homolog hits. The residual unannotated sequences were screened by FASTx against GenPept. Those hits with an E value of less than or equal to 10^{-8} are recorded as homolog hits.

Sequences were then reclustered using BLASTn and Cross-Match, a program for rapid protein and nucleic acid sequence comparison and database search (Green, *supra*), sequentially. Any BLAST alignment between a sequence and a consensus sequence with a score greater than 150 was realigned using cross-match. The sequence was added to the bin whose consensus sequence gave the highest Smith-Waterman score amongst local alignments with at least 82% identity. Non-matching sequences created new bins. The assembly and consensus generation

processes were performed for the new bins.

IV Coexpression Analyses of Known Inflammation Genes

Known inflammation genes were selected to identify novel genes that are closely associated with inflammation. These known genes were CD16, L-selectin, Src-like adapter protein (SLAP), IP-30, superoxidase holoenzyme subunits (p67phox, p47phox, and p40phox), alpha-1-antitrypsin (AAT), Clq-A, 5-lipoxygenase activating protein (FLAP), and SRC family tyrosine kinase (HCK).

The known inflammation genes that we examined in this analysis, and brief descriptions of their functions, are listed in Table 4.

Table 4. Known Inflammation Genes.

Gene	Description & references
CD16	receptor for IgG a.k.a. FcgammaRIII Phagocytosis of complement-generated immune complexes occurs through CD16 (Tamm et al. (1996) <i>J Biol Chem</i> 271:3659-66; Marsh et al. (1998) <i>J Immunol</i> 160:3942-8)
L-selectin	Leukocyte adhesion molecule Binds carbohydrate ligand on endothelial cell glycoprotein Adhesion is required for extravasation near inflammation site; auxiliary function in neutrophil activation during inflammation (Frohlich et al. (1998) <i>Blood</i> 91:2558-64; Girard and Amalric (1998) <i>Adv Exp Med Biol</i> 435:55-62)
SLAP	Src-like adapter protein Associated with Eck RPTK transduction pathway; Eck RPTK autocrine loop implicated in inflammation (Pandey, et al. (1995) <i>J Biol Chem</i> 270:19201-4; Pandey et al. (1995) <i>Science</i> 268:567-9)
IP-30	Functions in MHC Class II processing of peptides; implicated in inflammation, α -interferon inducible (Luster et al. (1988) <i>J Biol Chem</i> 263:12036-43; Arunachalam et al. (1998) <i>J Immunol</i> 160:5797-806; Schuelke et al. (1998) <i>Biochem Biophys Res Commun</i> 245:599-606)
p67phox,	superoxidase holoenzyme subunits
p47phox,	Macrophages utilize reactive superoxide in degradation of
p40phox	phagocytosed matter, induced by complement (Ratnam and Mookerjea (1998) <i>Immunology</i> 94:560-568)
AAT	alpha-1-antitrypsin (AAT) inhibits trypsin, a protease

Differentially expressed in inflammation, several alleles linked to chronic inflammatory disorders (Breit and Penny (1980) Aust NZ J Med 10:449-53; Takeuchi, Kobayashi et al. (1984) Int J Tissue React 6:1-8)

5 C1q-A First complement component, subcomponent q, subunit A (Alberts et al. (1994) Molecular Biology of the Cell, Garland Publishing, New York NY, p. 1214)

FLAP 5-lipoxygenase activating protein Lipoxygenase enzyme catalyzes formation of leukotrienes which are potent inflammatory mediators, FLAP is an anti-inflammatory therapeutic target (Byrum et al. (1997) J Exp Med 185:1065-75; Muller-Peddinghaus (1997) J Physiol Pharmacol 48:529-36)

10 HCK Src-family tyrosine kinase specific to hematopoietic cells Functions in integrin signaling, mouse knockouts have impaired inflammation response (Lowell and Berton (1998) Proc Natl Acad Sci 95:7580-4)

15

The coexpression of the 11 known genes with each other is shown in Table 5. The entries in Table 5 are the negative log of the p-value (- log p) for the coexpression of the two genes. As shown, the method successfully identified the strong association of the known genes among 20 themselves, indicating that the coexpression analysis method of the present invention was effective in identifying genes that are closely associated with inflammation.

We have also identified 11 novel genes that show strong association with known inflammation genes from a total of 41,419 assembled gene sequences. The degree of association was measured by probability values and has a cutoff of p value less than 0.00001. This was 25 followed by annotation and literature searches to insure that the genes that passed the probability test have strong association with known inflammation genes. This process was reiterated so that the initial 41,419 genes were reduced to the final 11 inflammation-associated genes. Details of the expression patterns for the 11 novel inflammation genes are presented in Table 5.

Each of the 11 novel genes is coexpressed with at least one of the known genes with a p-30 value of less than 10E-05. The coexpression of the 11 novel genes with the known genes are shown in Table 5. The entries in Table 5 are the negative log of the p-value (- log p) for the coexpression of the two genes. The novel genes identified are listed in the table by their Incyte clone numbers, and the known genes their abbreviated names as shown in Ex.5. V

Table 5. Coexpression analysis of novel genes with known inflammation genes(- log p).

		CD16	L-selectin	SLAP	IP-30	p67-phox	AAT	p47-phox	C1qA	p40-phox	FLAP	HCK	1221361	3055142	402234	3507924	1335016	3054032	569989	2349263	2471716	2726173	706377	
5	CD16	4																						
	L-selectin	5	6																					
	SLAP	5	6																					
	IP-30	5	3	4																				
	P67-phox	3	5	7	1																			
	AAT	6	2	4	1	5																		
10	P47-phox	5	6	5	1	7	3																	
	C1qA	7	2	6	1	3	7	6																
	P40-phox	5	5	3	4	7	4	6	1															
	FLAP	7	5	3	1	5	3	5	7	3														
	HCK	9	8	4	5	8	5	7	3	6	3													
	1221361	3	5	7	4	3	1	4	2	4	2	4												
15	3055142	6	5	9	4	5	3	8	1	4	3	8	4											
	402234	3	6	4	4	2	0	6	1	3	4	2	3	1										
	3507924	2	5	3	4	4	8	4	1	7	3	2	3	2	4									
	1335016	7	3	3	8	2	2	5	6	3	4	3	4	5	2	2								
20	3054032	5	11	9	5	4	4	7	7	7	8	7	5	7	5	4	4							
	569989	4	4	4	6	9	1	8	2	4	5	4	4	4	7	2	2	5						
	2349263	8	1	2	6	4	4	3	8	5	5	6	3	3	1	3	9	5	4					
	2471716	3	5	3	7	5	1	7	4	5	2	4	3	5	4	5	4	8	3	7				
	2726173	3	8	5	4	6	2	7	0	2	3	5	4	3	4	4	2	3	3	2	5			
25	706377	4	5	5	8	6	5	10	3	6	3	3	4	4	9	4	5	5	7	3	6	3		

V Novel Genes Associated with Inflammation

Eleven novel genes were identified from the data shown in Table 5 to be associated with inflammation.

Nucleic acids comprising the consensus sequences of SEQ ID NOs:1-11 of the present invention were first identified from Incyte Clones 402234, 569989, 706377, 1221361, 1335016, 2349263, 2471716, 2726173, 3054032, 3055142, and 3507924, respectively, and assembled according to Example III. BLAST and other motif searches were performed for SEQ ID NOs:1-11 according to Example VII. The sequences of SEQ ID NOs:1-11 were translated and sequence identity was sought with known sequences. Amino acids comprising the consensus sequences of SEQ ID NOs:12, 13, 14, 15, 16, and 17 of the present invention were encoded by the nucleic acids of SEQ ID NOs:1, 2, 6, 7, 8, and 11, respectively. SEQ ID NOs:12-17 were also analyzed using BLAST and other motif search tools as disclosed in Example VII.

SEQ ID NO:3 is 1229 nucleic acids in length and has about 99% match from about nucleic acid 250 to about nucleic acid 1216 with a human basement membrane-induced gene identified in

a human endometrial adenocarcinoma cell line (g3132521). SEQ ID NO:4 is about 1261 nucleic acids in length and has about 34% sequence identity from nucleic acid 23 to nucleic acid 994 with a predicted sequence similar to a RNA recognition motif (g2645068). SEQ ID NO:5 is 1340 nucleic acids in length and has about 60% sequence identity from about nucleic acid 21 to about 5 nucleic acid 925 with a human prostaglandin transporter hPGT mRNA (g3006201). The amino acid sequence encoded by SEQ ID NO:5 also exhibits several potential transmembrane domains as identified by HMM analysis. SEQ ID NO:9 is 2309 nucleic acids in length and shows similarity from about nucleic acid 104 to about nucleic acid 785 with a human polycystic kidney disease-associated protein gene (g790818).

10 SEQ ID NO:12 is 127 amino acid residues in length and shows about 50% sequence identity from about residue 37 to about residue 106 with a tobacco LIM-domain-containing protein (g1841464). The LIM domain is a cysteine-rich, zinc-binding motif of about 60 amino-acid residues that plays a potential role in DNA binding and regulation (Perez-Alvarado et al. (1994) *Nat Struct Biol* 1: 388-398). PFAM analysis shows that residues 40 to 97 of SEQ ID NO:12

15 encompasses the LIM domain. SEQ ID NO:13 is 93 amino acids in length and has a potential signal peptide sequence encompassing residues 1-18. SEQ ID NO:13 also exhibits a potential transmembrane domain encompassing residues 47 to 69. SEQ ID NO:14 is 225 amino acids in length and has about 32% sequence identity from about residue 5 to about residue 135 with a mouse high affinity IgE receptor beta subunit (g309225). SEQ ID NO:15 is 547 amino acid

20 residues in length and has about 35% sequence identity from about residue 413 to about 546 with a rat beta-chimaerin, a GTPase-activating protein expressed exclusively in the testis at the onset of sexual maturation (g203117). PFAM analysis shows that SEQ ID NO:15 has sequence homology from about residue 353 to about residue 523 with the GTPase-activator protein for Rho-like GTPases. SEQ ID NO:16 is 265 amino acids in length and shows about 93% sequence identity

25 from about residue 39 to about residues 265 with Maxp1, a rat protein which interacts with Ms4, a guanine nucleotide exchange factor (g2459833), and about 91% sequence identity from about residue 38 to about residue 265 with Nore1, a mouse putative Ras effector that plays an essential role in transmitting growth and differentiation signals received from Ras proteins(g2997698). This is confirmed by PFAM analysis that shows that SEQ ID NO:16 from about residue 119 to

30 about residue 211 matches a Ras association domain which interacts directly with the Ras proteins. SEQ ID NO:17 is 394 amino acids in length and exhibits a potential signal peptide sequence encompassing residues 1 to 19 and a potential transmembrane domain encompassing residues 273 to 295.

VI Homology Searching for Inflammation Genes and the Proteins

Polynucleotide sequences, SEQ ID NOs:1-11, and polypeptide sequences, SEQ ID NOs:12-17, were queried against databases derived from sources such as GenBank and SwissProt. These databases, which contain previously identified and annotated sequences, were searched for regions of similarity using BLAST (Altschul, *supra*) and Smith-Waterman alignment (Smith, *supra*). BLAST searched for matches and reported only those that satisfied the probability thresholds of 10^{-25} or less for nucleotide sequences and 10^{-8} or less for polypeptide sequences.

The polypeptide sequences were also analyzed for known motif patterns using MOTIFS, SPSCAN, BLIMPS, and Hidden Markov Model (HMM)-based protocols. MOTIFS (Genetics Computer Group, Madison WI) searches polypeptide sequences for patterns that match those defined in the Prosite Dictionary of Protein Sites and Patterns (Bairoch et al. *supra*), and displays the patterns found and their corresponding literature abstracts. SPSCAN (Genetics Computer Group) searches for potential signal peptide sequences using a weighted matrix method (Nielsen et al. (1997) *Prot Eng* 10:1-6). Hits with a score of 5 or greater were considered. BLIMPS uses a weighted matrix analysis algorithm to search for sequence similarity between the polypeptide sequences and those contained in BLOCKS, a database consisting of short amino acid segments, or blocks, of 3-60 amino acids in length, compiled from the PROSITE database (Henikoff and Henikoff, *supra*; Bairoch et al. *supra*), and those in PRINTS, a protein fingerprint database based on non-redundant sequences obtained from sources such as SwissProt, GenBank, PIR, and NRL-3D (Attwood et al. (1997) *J Chem Inf Comput Sci* 37:417-424). For the purposes of the present invention, the BLIMPS searches reported matches with a cutoff score of 1000 or greater and a cutoff probability value of 1.0×10^{-3} . HMM-based protocols were based on a probabilistic approach and searched for consensus primary structures of gene families in the protein sequences (Eddy, *supra*; Sonnhammer et al. *supra*). More than 500 known protein families with cutoff scores ranging from 10 to 50 bits were selected for use in this invention.

25 VII Labeling and Use of Individual Hybridization Probes

Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ - 32 P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (NEN Life Science Products, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine resin column (Amersham Pharmacia Biotech). An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (NEN Life Science Products).

The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to

NYTRANPLUS membranes (Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR film (Eastman Kodak, Rochester NY) is exposed to 5 the blots for several hours, hybridization patterns are compared.

VIII Production of Specific Antibodies

Any of the SEQ ID NOs:12-17, or fragments thereof, substantially purified using polyacrylamide gel electrophoresis (Harrington (1990) Methods Enzymol 182:488-495) or other purification techniques, is used to immunize rabbits and to produce antibodies using standard 10 protocols.

Alternatively, the amino acid sequence is analyzed using LASERGENE software (DNASTAR, Madison WI) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in 15 hydrophilic regions are well described in the art. Typically, oligopeptides 15 residues in length are synthesized using an ABI 431A Peptide synthesizer (PE Biosystems) using Fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester to increase immunogenicity. Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for 20 antipeptide activity by, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

What is claimed is:

1. A substantially purified polynucleotide comprising a gene that is coexpressed with one or more known inflammation genes in a plurality of biological samples, wherein each known inflammation gene is selected from the group consisting of CD16, L-selectin, Src-like adapter protein, IP-30, superoxidase homoenzyme subunits, alpha-1-antitrypsin, Clq-A, 5-lipoxygenase activating protein, and SRC family tyrosine kinase.
5
2. The polynucleotide of claim 1, comprising a polynucleotide sequence selected from:
 - (a) a polynucleotide sequence selected from the group consisting of SEQ ID NOs:1- 11;
 - (b) a polynucleotide sequence selected from the group consisting of SEQ ID NOs:12-17;
 - 10 (c) a polynucleotide sequence having at least 70% identity to the polynucleotide sequence of (a) or (b);
 - (d) a polynucleotide sequence which is complementary to the polynucleotide sequence of (a), (b), or (c);
 - (e) a polynucleotide sequence comprising at least 18 sequential nucleotides of the
 - 15 polynucleotide sequence of (a),(b), (c), or (d); and
 - (f) a polynucleotide which hybridizes under stringent conditions to the polynucleotide of (a),(b),(c), (d) or (e).
3. A substantially purified polypeptide comprising the gene product of a gene that is coexpressed with one or more known inflammation genes in a plurality of biological samples,
20 wherein each known inflammation gene is selected from the group consisting of CD16, L-selectin, Src-like adapter protein, IP-30, superoxidase homoenzyme subunits, alpha-1-antitrypsin, Clq-A, 5-lipoxygenase activating protein, and SRC family tyrosine kinase.
4. The polypeptide of claim 3, comprising a polypeptide sequence selected from the group consisting of:
 - (a) the polypeptide sequence selected from the group consisting of SEQ ID NOs:12-17;
 - (b) a polypeptide sequence having at least 85% identity to the polypeptide sequence of (a); and
 - (c) a polypeptide sequence comprising at least 6 sequential amino acids of the polypeptide sequence of (a) or (b).
- 25
5. An expression vector comprising the polynucleotide of claim 2.
6. A host cell comprising the expression vector of claim 5.
7. A pharmaceutical composition comprising the polynucleotide of claim 2 or the polypeptide of claim 3 in conjunction with a suitable pharmaceutical carrier.
- 30

8. An antibody which specifically binds to the polypeptide of claim 4.
9. A method for diagnosing a disease or condition associated with the altered expression of a gene that is coexpressed with one or more known inflammation genes, wherein each known inflammation gene is selected from the group consisting of CD16, L-selectin, Src-like adapter protein, IP-30, superoxidase homoenzyme subunits, alpha-1-antitrypsin, Clq-A, 5-lipoxygenase activating protein, and SRC family tyrosine kinase, the method comprising the steps of:
 - (a) providing a sample comprising one of more of said coexpressed genes;
 - (b) hybridizing the polynucleotide of claim 2 to said coexpressed genes under conditions effective to form one or more hybridization complexes;
 - (c) detecting the hybridization complexes; and
 - (d) comparing the levels of the hybridization complexes with the level of hybridization complexes in a non-diseased sample, wherein the altered level of hybridization complexes compared with the level of hybridization complexes of a nondiseased sample correlates with the presence of the disease or condition.
10. A method for treating or preventing a disease associated with the altered expression of a gene that is coexpressed with one or more known inflammation genes in a subject in need, wherein each known inflammation gene is selected from the group consisting of CD16, L-selectin, Src-like adapter protein, IP-30, superoxidase homoenzyme subunits, alpha-1-antitrypsin, Clq-A, 5-lipoxygenase activating protein, and SRC family tyrosine kinase, the method comprising the step of administering to said subject in need the pharmaceutical composition of claim 7 in an amount effective for treating or preventing said disease.
11. A method for treating or preventing a disease associated with the altered expression of a gene that is coexpressed with one or more known inflammation genes in a subject in need, wherein each known inflammation gene is selected from the group consisting of CD16, L-selectin, Src-like adapter protein, IP-30, superoxidase homoenzyme subunits, alpha-1-antitrypsin, Clq-A, 5-lipoxygenase activating protein, and SRC family tyrosine kinase, the method comprising the step of administering to said subject in need the antibody of claim 8 in an amount effective for treating or preventing said disease.
12. A method for treating or preventing a disease associated with the altered expression of a gene that is coexpressed with one or more known inflammation genes in a subject in need, wherein each known inflammation gene is selected from the group consisting of CD16, L-selectin, Src-like adapter protein, IP-30, superoxidase homoenzyme subunits, alpha-1-antitrypsin, Clq-A, 5-lipoxygenase activating protein, and SRC family tyrosine kinase, the method comprising the step of administering to said subject in need the polynucleotide sequence of claim 2 in an amount

effective for treating or preventing said disease.

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.
WALKER, Michael G.
VOLKMUTH, Wayne
KLINGLER, Tod M.

<120> INFLAMMATION-ASSOCIATED GENES

<130> PB-0006 PCT

<140> To Be Assigned
<141> Herewith

<150> 09/195,292
<151> 1998-11-18

<160> 17

<170> PERL Program

<210> 1
<211> 1298
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 402234CB1

<400> 1
gggacatgac ttagggaaag tcccaacccg aatccccca gcccctgcct gtcaacaccc 60
cccacccctgc aggctggggc cgggctggcg gggccctccc gactgacttc cccttgcaga 120
accaggcggg tgccgcttct ccacccgagg cttccacctc caacgagcca tttccaggc 180
tgcaggagcc gcccaggcca cccccctctca tgacgccaaa ggcggcggca gcagcacgg 240
gcagcgctcc aagtccctca gcctgcgggc ccaggtgaag gagacctgcg ccgcctgcca 300
gaagaccgtg tacccatgg agcggctgtt ggccgacaag ctcatttcc acaactcttg 360
cttctgctgc aagcaactgtc acaccaagct cagccctggc agctacgcgg cgctgcacgg 420
ggagttctac tgcaaaacccc acttccagca gctgtttaag agcaaaggca actacgacga 480
ggggtttggc cgcaaggcagc acaaggagct ctgggcccac aaggaggtgg accccggcac 540
caagacggcc tgaggcctct gtaaccttcc accccctctg cggaaaggcct ggagccggca 600
gggggaaggt gggaaaggagg tcgagctggg cttgcgtggg ggccagggtgg gaaggggatg 660
agcttgctc aggcgttaggg gaccaggcca gggctctgct ccaggactcc ttcccttcttc 720
cttctcccgc agccgtgtgag gttttggaaa ccaggtattgg ggtctgccc ccaccctgct 780
tctctgcttc ttcagcctcc ctccccacact caccctcaggaa cccctggga ggcccccac 840
cccagctccc ctatcttaggt gccttttctc cagaaggag tcagcatgcc cccctcagg 900
tcccaagctc cctcaactgcc accggagact gtgtggccccc cacgtctccc catctacctc 960
tacccttaac ctgtttctga gccacggaga cagggaggaa ggagcgcgac agtgcac 1020
gttgggcata ataaatggcc ctgcagccca tgggggagga gatggggaaat tggagccacc 1080
ctgcctctgc agggcaaggc agggcctgcc ccagtggggc ttgggaccat ctgcgaaccac 1140
cagcgtggag aagcagaagc aaaaggactc gccaggctgc agcctcaggc actggcagg 1200
gctgggtgcgg ccccactccc ctcccccgct cccatttttg cccatccctgt ttttgcac 1260
cccgtttaaa acatgtttca atagatccaa aaaaaaaaaa 1298

<210> 2
<211> 532
<212> DNA
<213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 569989CB1

<400> 2
 cccacgcgtc cgcccttgaca ccagcagggt gacatccgct attgctactt ctctgctccc 60
 ccacagtcc tctggacttc tctggaccac agtcctctgc cagaccctg ccagacccc 120
 gtccaccatg atccatctgg gtcacatctt cttcctgctt ttgctccag tggctgcagc 180
 tcagacact ccaggagaga gatcatcaact ccctgcctt taccctggca cttcaggctc 240
 ttgttccgga tgtgggtccc tctctctgcc gctcctggca ggcctcgtgg ctgctgatgc 300
 ggtggcatacg ctgctcatcg tggggcggt gtcctgtgc gcacgcccac gccgcagccc 360
 cgcccaagaa gatggcaaag tctacatcaa catgccagggc aggggctgac cctcctgcag 420
 cttggacctt tgacttctga ccctctcatc ctggatggtg tgtggtgca caggaacccc 480
 cgcccaact tttggattgt aataaaacaa ttgaaacacc aaaaaaaaaa aa 532

<210> 3
 <211> 1229
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 706377CB1

<400> 3
 cagagagccg cggggaccat ggagccggtg ccgctgcagg acttcgtgcg cgccttggac 60
 cccgcctccc tcccgcggt gctgcgggtc tgctcgggg tctacttcga gggctccatc 120
 tatgagatct ctggaatga gtgctgcctc tccacgggg acctgatcaa gtcacccag 180
 gtccgcctcc agaaggtggt ctgtgagaac ccgaagacca gccagaccat ggagctcggc 240
 cccaacttcc aggtcttctc aagtcttagg attgcagcaa cacgctcggc tgcccaaacc 300
 caaggcgaag accttgccag agttcatcaa ggatggctcc agtacgtaca gcaagattcc 360
 tgcccacagg aagggccaca ggccgctaag cccaaaggc aggatctaga tgatgatgaa 420
 catgattatg aagaataact tgagcaatt cagaaaaacca tctaagtgcg ggaggaacca 480
 cgcttcctaa ctgctgcctc tcagggaaatc cgacaccagc caaccattt aagcctctaa 540
 aagacctcgg gcaagtctca cagaaaactga gctgcagacg gggagtagct ttgtggaaac 600
 tgatttgatg gacactgcac cagttccctt cagttctag attcttgcta cttagggccg 660
 gctggtttgg acctaacatc tcgcacgtga ctccctcagc ctcaagaccc tggatgcag 720
 acgagctggc agggttcctc tcaatcctgc aaccctcagct gtccaccgg tggatgcaga 780
 gggaaatccg aggccatcaa ctttggtgac agcagcgcag tgccaatgcg gatcacactg 840
 catgggagat ttgttaacg tctgccaccc ccactctcac cccaaagctc taagccccgg 900
 ggaggcctgg actgtttcc tcatctctgt agcacaaggc ctgataagatc tgtatatgg 960
 aaacaggggt ttaaccacat gtggtaaca tggattaatg tggaaacttg gcttcaagaa 1020
 cacaacctta ggaccttggg ccccaaaacg tgggtgtgaa atgaggagga gccaatttaa 1080
 gaagaccctt atggagacac gaggctgcag aaactggtag gtttcatcg gtggtaaaag 1140
 tcgtcaaagt tgtaagtgcac taaccaagat tatttcattt taaaaccata gaataaaaat 1200
 gacacctgag cttctctaaa aaaaaaaaaa 1229

<210> 4
 <211> 1261
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 1221361CB1

<400> 4
 cggacgcgtg ggcggacgcg tggcggacgc gtgggcggac gcgtgggcgc gatgggcctc 60
 ttggaacatt ggtgtgttca tctgcattcg atgtgctgga atccacagga atctgggggt 120
 gcacatatacc agggtaaaagt cagttacact cgaccaggcgg actcaagaac agattcagtg 180
 catgcaagag atggaaaatg gaaaggcaaa ccgactttat gaagcctatc ttcctgagac 240

ctttcggca	cctcagatag	acccagctgt	tgaaggattt	attcgagaca	aatatgagaa	300
gaagaatatac	atggaccgaa	gtctggacat	caatgcctt	aggaaagaaa	aagatgacaa	360
gtggaaaaga	gggagcgaac	cagttccaga	aaaaaaaattg	gaacctgtt	tttttgagaa	420
ggtgaaaatg	ccacagaaaa	aagaagaccc	acagctacct	cgaaaaagct	ccccgaaatc	480
cacagcgccct	gtcatggatt	tgttggcct	tgatgctcct	gtggcctgct	ccattgcaaa	540
tagtaagacc	agcaataccc	tagagaagga	tttagatctg	ttggcctctg	ttccatcccc	600
ttcttcttcg	ggttccagaa	aggttgtagg	ttccatgcc	actgcaggga	gtgcccggctc	660
tgttcctgaa	aatctgaacc	tgtttccgga	gccaggagc	aaatcagaag	aaataggcaa	720
gaaacagctc	tctaaagact	ccattcttc	actgtatgga	tcccagacgc	ctcaaatgcc	780
tactcaagca	atgttcatgg	ctccccgtca	gatggcatat	ccacagcct	accccaagctt	840
ccccggggtt	acacctccta	acagcataat	ggggagcatg	atgcctccac	cagtaggcat	900
ggttgctcag	ccaggagctt	ctgggatgg	tgccccatg	gcatgcctg	caggtatata	960
gggtggcatg	caggcatcaa	tgatgggtgt	gccgaatgga	atgatgacca	cccagcaggc	1020
tggctacatg	gcaggcatgg	cagctatgcc	ccagactgtg	tatggggtcc	agccagctca	1080
gcagctgcaa	tgaacacctt	ctcagatgac	ccagcagatg	gctggatga	acttctatgg	1140
agccaatggc	atgatgaact	atggacagtc	aatgagtggc	gaaatggac	aggcagcaaa	1200
tcagactctc	agtccctcaga	tgtggaaata	aaaacaaaaac	accttgtata	aaaaaaaaaa	1260
a						1261

<210> 5

<211> 1340

<212> DNA

<212> DNA

<220>

<221> misc feature

<223> Incyte ID No.: 1335016CB1

<400> 5

ccctcgaaat	tcggctcgag	cagcaactcg	cccccttacc	tcgggatcct	gtttgcagtg	60
accatgatgg	ggccaggcct	ggccttggg	ctgggcagcc	tcatgctcg	cctttatgtg	120
gacattaacc	agatgccaga	agggtgtatc	agcctgacca	taaaggacc	ccgatgggtg	180
ggtgccttgt	ggctgggtt	cctcatcgct	gccgtgcag	tggccctggc	tgccatcccc	240
tacttcttct	tccccaaagg	aatgcccag	aaaaaacgtg	agcttcagtt	tcggcggaaag	300
gtcttagcag	tcacagactc	acctgcccagg	aagggcagg	actctccctc	taagcagagc	360
cctggggagt	ccacgaagaa	gcagggatggc	ctagtcaga	ttgcaccaaa	cctgactgtg	420
atccaggta	ttaaagtctt	ccccagggtg	ctgctgcaga	ccctacgcca	ccccatcttc	480
ctgctgtgg	tccctgtcccc	ggtatgcttg	tcatccatgg	ctgcgggcat	ggccaccccttc	540
ctgccccaaagt	tccctggagcg	ccagtttcc	atcacagct	cctacgcca	cctgtcatc	600
ggctgcctct	ccttcccttc	ggtcatcg	ggcatcg	tgggtggcgt	cctggtaaag	660
cggctccacc	tggggccctgt	gggatgcgg	gcccttgc	tgctgggat	gctgctgtgc	720
ctcttcttca	gcctgcccgt	cttccttata	ggctgctcca	gccaccagat	tgcgccatc	780
acacaccaga	ccagtgc	ccctgggctg	gagctgtctc	caagctgc	ggagggctgc	840
tcctgc	ccat	tggacggctt	tgcgacccca	gcaactcg	gaaatacatc	900
acaccctg	cc	taaccctgtc	gtggtccagg	atgctctgg	caacagccag	960
agtcttccca	cctccaccc	tcaactgtgg	catcagatc	taaacctg	gtccctccag	1020
ggagagac	ctt	tcatgtgg	aaagaac	ttgatgg	atagtccttc	1080
agaagcc	cc	ggcact	gac	tttgc	aggccttggc	1140
aggtggag	ca	gtggatatgg	aaatc	tttgc	taggcctcta	1200
actgactct	gttac	aaattat	aactagtg	tcagtttctt	ggctgttaa	1260
ataggggaga	tattat	tgctactac	agagcaggaa	tgtgctgaat	aaatgc	1320
cctggatgaa	aaaaaaa					1340

<210> 6

<211> 2192

<212> DNA

<212> DNA

<220>

<221> misc feature

<221> misc_feature

<210> 7
<211> 1992
<212> DNA
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incyte ID No.: 2471716CB1

```

<400> 7
agaaaactgt gagagagaga attttaaaaa agcagctggg gcctgaggtt tctcccccag 60
taccctgggt cacctcagcc cagagctggc ggcaggcccc cagccccctca tgtcagagcc 120
ccctgtgtac tctaaccctgg tggaccttcg ccgctgtcct cggtccccac ccccaaggccc 180
tgcattttttt ctgctgcaga ggctggatgc ctgggagcag cacctggacc ccaactctgg 240
acgctgtttc tacataaaatt cactgactgg ctgcaagtcc tggaaagcccc cgccgcgcag 300
tcgcagcgag acgaaccctg gtcacatggg ggggacacag accctgaaga ggaacaatga 360
tgtctgtcaa cctcaggcaa agggcttcag atctgacaca gggaccccaag aaccgcttga 420
cccacagggt tcactcagcc tcagccaaacg cacctcgcaag ctgtacccttc cagcccttgca 480
ggccccctcga cctctgcccgc agctcctggg cgaccccccatt gaggtggaaa agtcgggtct 540
gctcaacatg accaagattt cccaaaggggg gcgcaagctc aggaagaact gggcccgctc 600
ttgggtgggt ttaacgggta acagcctggt gttctaccga gagccaccgc cgacacgcgc 660
ctccctcaggc tggggaccag cgggtagccg gccccaaagt agcgtggacc tgcgccgggc 720
ggccctggcg cacggccgc acctgtccag cccgcgaac gtctgcaca tccgcacgat 780

```

ccctggccac	gagttcctgc	tgca	gtcgga	ccacgagaca	gagctgcgag	cctggcaccg	840
cgcgctgcgg	actgtcatcg	agc	ggctgga	tccggagaac	cccctggagc	tgcgtctgtc	900
gggcctctgg	cccgcggagc	tgagg	ccgg	ggaggacgaa	gaagaggagt	cggagctgg	960
gtccaa	ctgctgcgc	tcag	ccgg	ccggagctcc	attcgggggc	ccgaaggcac	1020
cgagcagaac	cgcgtgcga	acaaactaaa	gcgg	gcga	agagagac	cgccttaca	1080
aagcctgcag	gagcgggggtc	tgctccgaga	ccagg	ggtgc	caagt	tggaatca	1140
ctgcca	gaaggagaca	cgg	cttttgcgg	ctctgcattt	ctgctgtgg	1200	
taaaagaggt	ctagatgtgg	atggcattt	tcgggtgagc	gggaacttgg	cagtgg	tcca	1260
gaagctcgc	tttctgggtgg	acagagagcg	tgcggtcacc	tccgatggga	ggtatgtgtt	1320	
cccagaacag	ccaggacaag	aagg	agatttgac	agat	actgag	gggatgacat	1380
tcatgtggtc	accggagccc	tga	tctccggag	ctgccc	cact	ctctgtgtcc	1440
accactgtc	ctgccccatt	tccg	ccttgactc	tccga	atcag	agcagtgcct	1500
ctctcagata	caagaattaa	taggt	ccaa	aaccatgaca	ctctacggta	1560	
cctctggag	catttatgca	gggt	acat	aa	atcgca	tgacacccca	1620
caacctgg	atttgtttt	gatagc	actacat	aa	atcgca	catctgaccc	1680
agcagccat	gctcttacc	gacca	gttcc	gg	atgtc	acttcaccag	1740
cctcttcccc	tgatgcaggg	aa	agat	aa	accata	tctctgtgg	1800
tgagaggctg	gtgttctgtt	gg	tttccgtca	tttccgtca	tctctgtgg	1860	
tcttcatgag	tgtgacttga	gg	ttccctgtt	ttccctgtt	tcattcctcc	ccgaacataa	1920
tgagtggatt	aacccctgtct	tt	taatacataa	gt	1980		

```
<210> 8
<211> 3144
<212> DNA
<213> Homo sapiens
```

<220>
<221> misc_feature
<223> Incyte ID No.: 2726173CB1

```

<400> 8
ccttgatgct ctggcgccct cggccgggaa ctccgggta gatgaccgtg gacagcagca 60
tgagcagtgg gtactgcagc ctggacgagg aacttggaa aacttggaaa ctgcttcttc actgctaaga 120
ctacctttt cagaaatgcg cagagcaaac atcttcaaa gaatgtctgt aaacctgtgg 180
aggagacaca ggcggccccc acactgcagg agatcaagca gaagatcgac agctacaaca 240
cgcgagagaa gaactgcctg ggcattgaaac tgagtggaa cggcacctac acgggttca 300
tcaaagtgc tctgaaactc cggccgcctg tgacggtgcc tgctgggatc cggcccccagt 360
ccatctatga tggccatcaag gaggtgaacc tggcggtac cacggacaag cggacatcct 420
tctacctgcc ccttagatgcc atcaagcagc tgcacatcg cagcaccacc accgtcagtg 480
aggtcatcca ggggctgctc aagaagttca tgggtgtgga caatccccag aagttgcac 540
tttttaagcg gatacacaag gacggacaag tgctcttcca gaaactctcc attgctgacc 600
gccccctcta cctgcgcctg cttgctggc ctgacacgga ggtcctcaac tttgtctaa 660
aggagaatga aactggagag gtagagtggg atgccttcc catccctgaa cttcagaact 720
tcctaacaat cctggaaaaa gaggagcagg acaaaatcca acaagtgc当地 aagaagtatg 780
acaagttag gcagaaaactg gaggaggcct taagagaatc ccaggc当地 cctggtaac 840
cggctctgtc tccctcttc ctgggtcatt cagatttatt tgatttattt attattattt 900
tgcaacagac acttttctc aggacatctc tggcagggtc atttgtgc当地 gcccagcagt 960
tccagctgtc gcaaaaagtct cttccatggc caagtgttg cacggggggtt cagctgtgcc 1020
cgcccccagg ctgtgccccca ccacagattc tgccaaagat cagaactcat gtgaaacaaa 1080
cagctgacgt cctctctcga tctgcaagcc tttcaccaac caaatagtt cctctctcgt 1140
caccaaactg gaaacctcaca ccagccggca aaggaagggaa gaaagggtt agagctgtgt 1200
gttctttctc tggctttgat tcttcttgc gttctttac ttgcacgtc caggaccatt 1260
atttatgagt gaaaagttgt agcacattcc ttttgcagggt ctgagctaa ccttggaaag 1320
cagggtaatg ctcataaaag gactgttccc gcgcccccaa ggtgcctgtt gttcacact 1380
aagggaagtt tataaagcta ctggcccccag atgctcagggt taaggagcac caaagctgag 1440
gctggctcag agatctccag agaagctgca gcctgcctg gcctggctc tggccctggc 1500
ccacattgca catggaaaacc caaaggcata tatctgcgtc tttgtggatc ttatgcacat 1560
ctttgtcaac aaactgttcg ttttaagtt acaaatttgat atttaatgtt gtcatacatcg 1620
ccatgtgttt ccccaaaggg aagccagtca ttgaccattt aaaaagtctc ctgctaagta 1680
ggaaatctcg acagtaagag aaagccaaaa agcaatgcag agaaagggtt ccaagctgtc 1740
ttcagccttc cccagctaaa gaggcagagga gggcctggc tacttgggtt cccatcgcc 1800

```

ctccagact	gcctccctcc	tcccactgcg	actctggat	ctccaggtgc	tgcccaagga	1860
gttgccttga	ttacagagag	gggagcctcc	aattcggcca	acttggagtc	ctttctgttt	1920
tgaagcatgg	gccagaccgg	gcactgcgt	cgagagccg	gtgggcctgg	cctccccgtc	1980
gacctcagtg	ccttttgtt	ttcagagaga	aataggagta	ggcgagttt	gcctgaagct	2040
ctgctgctgg	cttctccctgc	caggaagtga	acaatggcgg	cggtgtggg	gacaaggcca	2100
ggagagcccg	cgttcagtat	gggttgaggg	tcacagacct	ccctcccatc	tgggtgcctg	2160
agttttgact	ccaatcagtg	ataccagacc	acattgacag	ggaggatcaa	attcctgtact	2220
tacatttgc	ctggcttctt	gtttagctg	aatcctaaaaa	taaattagtc	aaaaaatcc	2280
aacaagtagc	caggactgca	gagacactcc	agtgcagagg	gagaaggact	tgttaatttc	2340
aaagcaggc	tggttttcca	accgcagctc	tgaaaaacca	tttctttgct	atcctctgcc	2400
ttcccaagtc	cctcttgggt	cggttcaagc	ccaagcttgc	tcgtgtagct	tcagaaggtc	2460
cctctccgac	ccaggctgag	tccatactgc	ccctgatccc	agaaggaatg	ctgaccctc	2520
gtcgtatgaa	ctgtgcata	tctccagagc	ttcaaaaggca	acacaagctc	gcaactctaa	2580
gatttttta	aaccacaaaa	accctggta	gccccatctcat	gctcagcctt	atcacttccc	2640
tccctttaga	aactctctcc	ctgctgtata	ttaaaggggag	cagggtggaga	gtcatttcc	2700
ttcgtctcgtc	atgtctctaa	cattaataga	agcatggct	cctgctgcaa	ccgctgtgaa	2760
tgctgcttag	aacccccc	tatggggatg	gctatttat	ttttgagaag	aaaaaaaaaa	2820
gtcatgtata	tatacacata	aaggcatata	gctatata	aagagataag	ggtgttatg	2880
aaatgagaaa	attattggac	aattcagact	ttaactaaagc	acagttagac	ccaaggccta	2940
tgctgaggtc	taaacctctg	aaaaaagtat	atgtcgagt	acccttccc	tcccagaggt	3000
gggagtaact	gctggtagtg	ccttcttgg	tttgttgc	cagtgttaa	gtgtttgtt	3060
ccaggatatt	ttcttttaa	atgtcttct	tatatgggtt	ttaaaaaaaaa	gtaataaaaag	3120
cctgttgc	aaatgaaaaa	aaaa				3144

<210> 9
<211> 2309
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 3054032CB1

<400> 9

aaggggccca	ggaagatcaa	gttgctgagg	agaaatgggg	aggaagttt	cctgagtgcc	60
tatgtgacc	taagtccct	tctggaccc	aaaccccca	tctggaaagg	ttcagggagt	120
ctggagggag	aggcagcagg	atgtggagg	caggctctgg	gacagggtgg	ggaagagcag	180
gcatgctggg	aagtgggg	ggacaagcag	gctgagcctg	gaggcaggct	agacatcagg	240
gaagagggcag	agggaagtcc	agagaccaag	gtggaggctg	gaaaggccag	tgaggataga	300
ggggaggcgt	ggggaaagcc	agagacaaaa	gtcagattga	gagaaggggag	taggaaagag	360
acagaggc	aggaaagagaa	gtccaaaggt	cagaagaagg	ctgacagtat	ggaggctaaa	420
ggtgtggagg	aaccaggagg	agatgagtat	acagatgaga	agaaaaaaga	aattgagaga	480
gaagaggatg	aacaaagaga	ggaagccca	gtagaagctg	gaagggaccc	agagcaaggg	540
gccccaggaag	atcaagttgc	tgaggagaaa	tggaaagt	tacagaaaca	agaggctgag	600
ggagtcagag	aggatgagga	caaaggacag	aggagaagg	ggtaccatga	agcaagaaaa	660
gaccaaggag	atggtaaga	cagcagaagc	ccagaagcag	caactgaagg	aggagcaggg	720
gaggtcagca	aggaacggg	gagtgggat	ggagaggctg	agggagacca	gagggctgga	780
gggtactatt	tagaagagga	caccctct	gaaggttc	gtgtagcgtc	cctggaggtt	840
gactgtgcca	aagagggcaa	tcctcact	tctgagatgg	aagagtagc	cccacagcc	900
cctcagccag	aggagatgga	gcctgagggg	cagcccagtc	cagacggctg	tctatgcccc	960
tgttctctt	gcctgggtgg	cgtggccat	cgtagctt	ccactcttgt	tcaggtccaa	1020
caggccgc	ctgtgcctgt	ggtcccccc	aagccacagt	ttgccaagat	gcccagtgc	1080
atgtgttagca	agatccatgt	ggcacctgca	aatccatgcc	cgaggcctgg	ccggcttgat	1140
gggactcctg	gagaaagggc	ttgggggtcc	cgagcttctc	gatcccttgc	gaggaatggg	1200
ggtagtctt	ccttgcgtc	tgctgtggcc	ctagccccgg	accgcacaa	gactgaggt	1260
caaggagttc	ggcgaaccca	gacctgtact	gagggtgggg	attactgc	catccccaga	1320
acctccctt	gtagcatgt	ctctgc	cccttgc	cctggagtc	1380	
ccatctgaag	gtgcagaagg	gtctggatcc	cggagtcgtc	ttagtc	ccccagagaa	1440
ccccaggttc	ctgacccct	gttgtccct	cagcgcagat	catatgcatt	taaaacacag	1500
gctaaccctg	ggaaaggtga	aggactgtga	ttaggaccac	agccctggc	aaaggggacc	1560
agcaagttgt	cttgaatctc	cagggttcc	gactagctgt	ctcctctgca	gcatgagcag	1620
ctgttagtgc	caactctata	ggcttggcc	ctccagcttc	tcttttgac	tgtggaggc	1680

actgccttgg	ttgggttt	tgaacttgtc	tccgacacaa	agcaacttac	tttaggaga	1740
ttccccaaagaa	agtcaacaag	atcttggttcc	cagggagtg	gtcattggcc	aaaggaaaca	1800
taaggtaggc	agaaaaactta	aaagagttt	ttaaagtga	gactggagaa	attcctccct	1860
tcctctgagc	tgtgaatctc	tcttcatgaa	agccaaaggt	agagacaggg	aggacagggc	1920
caggtaggg	ccttccacac	acaaaacactt	ctagagttgc	ccattcctgt	tatgttcttg	1980
gaccctaaga	tacctcctgt	ccctttaaa	tccagattaa	gagaaaacgtc	caggaagagc	2040
tctttgaagc	cctcaatatt	tgttggaggg	actggactcc	tctccagctc	cccaccctct	2100
gcctccagtc	accatgtgca	agagaggtcc	tgtacagatc	tctctggct	ctcctttctc	2160
ctttggata	acttggttcct	atttcaggaa	agggaaatgg	tgtcaactcag	gcccctggac	2220
tgcttctcca	gccaggctgg	ggccacaggt	cccactctag	tgaaggtcaa	tgtctcagaa	2280
taaaagctgt	atttttacaa	aaaaaaaaaa				2309

<210> 10
<211> 1666
<212> DNA
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incyte ID No.: 3055142CB1

<400> 10
ctgctcgaga actgaatggc cctgtgcaga gccatagtc cactgtgggt cctgcaatga 60
gcaggggctg ggagtagagg gtttctgggg cctcagggtt ctggaaagc aacagctatc 120
agagagagaa gggccagacc ccatagcctc ttagattctt ggcagtagaa ggagaaggat 180
ggtaatttgc acctctgaag tccctgacca ttagcatggt ctaggatctt ttctagaagg 240
aagatctgag gctctgggtc tcagggggat ggcttggcc ttttctctca accttgctg 300
agcctacccc ttactttgcc aaagacttga ggaccctgtt tgctggagt tcagtcctt 360
cctctgtggg gctcagggtt ttgaaatgtt gatgaaaacat ttctctactt caagaccacc 420
tctccctgca aacaccacac acacatggca tgcatgtacg cacatgcgca cacacacacg 480
cacacaccc aataatttct ctcaagttt ctgagtcctt agaaaaacag cactaacgct 540
ggacacctt actctcagaa cccggcacag attctcttctt gatctcctt tgaaatctga 600
gattcttaga agacaggata gggtaattt tagtagcagc tcagttctag ctaaatact 660
agaggaagtt aattaacttt aagccttcatt ttctccagca ctaaaatggg gtggagagtt 720
gggggtggaaa taagacatcc ttaaaagggtt aaattgtctg caaagcacct agcccagtgc 780
cgagctccca gtaggtgtt agtaaagctt agtgcctgac ttctgaaca ctgatttcctc 840
ctgtttggag tcactggat actctcattt ccgttgggtt gttcctcact cttcccagt 900
tcgtggctga ggcaaaaccc agactgaaga gggaaagagac attccagagg aggattgcct 960
tcgtcagggt aagggtggg ctgctcaggg gccttaccct tcacccctt ctgtatcaga 1020
ttggccctcc cactccatc tcactctgcg tgcataatct tccatatccg caagttcact 1080
ggcactcttc tggcacctgg gcaagatccc agaacacaggat atggagtgc tggcctcaca 1140
gagcttagt cccgactcag gggaaatggg actgggtcat gggaaatggt cagcttagga 1200
taggacacga gagtctgaaa ttcaaaagcaa ccagcttggaa gtgggtttag aagctggaaag 1260
caaacatggg ctagagagat agggcagaag tcaagacgag gatctggact gatgtggaga 1320
aagttagccac ggaagcatga actgtatctt gcacaaaagtc cctcttccca gcctcctaata 1380
ccattatgcc caaaaggctt tacgtaaaat tccagcccaag agtactcatg acttgagaga 1440
cgtggacaga gccagcttctt accttgcctt ggcgtctctt ccctgtctta atgtctgctc 1500
ttgtcttaag ctccagaaga gtggcggggcc atgtatctt aatatgttt tgctgtatgg 1560
caggttgtc ttattatgtt atcaacagat gtccaggaac taatgagtgg aatttaatata 1620
attgtcaaa taaaacttgc ttgtccat aaaaaaaaaa aaaaaaa 1666

<210> 11
<211> 1751
<212> DNA
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incyte ID No.: 3507924CB1

<400> 11

ttttagaggtt cctgtttgca tctctgcaac cacttcagaa ggcacgtgtt tggtttgctc 60
 tgagcctaac ctagagtgtc cgcaagcagtc tttcagttga gcttggggac tgcagctgtg 120
 gggagattc agtgcattgc ctccccctgg tgctcttcat cttggatttga aaagttgaga 180
 gcagcatgtt ttgcccactg aaactcatcc tgctgccagt gttactggat tattccttgg 240
 gcctgaatga cttgaatgtt tccccgcctg agctaacaatggtt ccattgtgggt gattcagctc 300
 tgatggatg tggatggatg agcacagaag acaaataatgat attcaagata gactggactc 360
 tgtcaccagg agagcacgccc aaggacgaat atgtgtata ctattactcc aatctcagtg 420
 tgcctattgg ggcgttccag aaccgcgtac acttgtatggg ggacatctt tgcaatgtatg 480
 gctctctcct gctccaagat gtcaagagg ctgaccaggg aacctataatc tggatggatc 540
 gcctcaaaagg ggagagccag gtgttcaaga aggccgtggt actgcattgtg cttccagagg 600
 agcccaaaga gctcatggtc catgtgggtg gattgattca gatgggatgt gttttccaga 660
 gcacagaatg gaaacacgtg accaaggtag aatggatatt ttcaggacgg cgccaaagg 720
 aggagattgtt atttcgttac taccacaaac tcaggatgtc tggatggatc tcccagagct 780
 gggccactt ccagaatcgt gtgaacctgg tgggggacat tttccgcaat gacggttcca 840
 tcatgttca aggagtggg gagtcaatgt gaggaaacta caccgtcgtt atccacccatg 900
 ggaacctgtt gttcaagaaa accattttgtc tgcattgtcag cccgaaagag cctcgaacac 960
 tggtgaccggc ggcgcctgg aggccctctgg tcttgggtgg taatcgttgc gtgatcattg 1020
 tggaaattgt ctgtgccaca atcctgtcgc tccctgttct gatattgtatc tggatggatc 1080
 cctgtggaaa taagagttca gtgaatttcta cagttttggt gaaagaaacacg aagaagacta 1140
 atccagagat aaaagaaaaaa ccctgcatt ttgaaagatg tgaaggggag aaacacattt 1200
 actccccat aattgtacgg gaggtgatcg agaagaaga accaagtgaa aaatcagagg 1260
 ccacacat gaccatgcac ccagtttggc cttctctgtc gtcagatcgg aacaactcac 1320
 ttgaaaaaaaaa gtcagggtgg ggaatgcca aaacacacgca agcctttgt gaaagatgg 1380
 gagttcccttc atctcagcag cgggtggagac tctctctgt gtgtgtcctg ggccactcta 1440
 ccagtgattt cagactcccg ctctcccgat tgcctctctg tctcattgtt tggtaataac 1500
 actgaagatg gagaattttgg agcctggcag agagacttgg cagctctgg ggaacagggc 1560
 tgctgagggg aggggagcat ggacttggcc tctggatgtt gacactggcc ctggaaacca 1620
 ggctgagctg agtggcctca aaccccccgt tgatcagac cctcctgtgg gcagggttct 1680
 tagtggatga gttactggg agaattcagag ataaaaacca acccaaataca ttcctctggc 1740
 aaaaaaaaaa a 1751

<210> 12

<211> 127

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 402234CD1

<400> 12

Met	Phe	Gln	Ala	Ala	Gly	Ala	Ala	Gln	Ala	Thr	Pro	Ser	His	Asp
1									10					15
Ala	Lys	Gly	Gly	Gly	Ser	Ser	Thr	Val	Gln	Arg	Ser	Lys	Ser	Phe
									20					30
Ser	Leu	Arg	Ala	Gln	Val	Lys	Glu	Thr	Cys	Ala	Ala	Cys	Gln	Lys
									35					45
Thr	Val	Tyr	Pro	Met	Glu	Arg	Leu	Val	Ala	Asp	Lys	Leu	Ile	Phe
									50					60
His	Asn	Ser	Cys	Phe	Cys	Cys	Lys	His	Cys	His	Thr	Lys	Leu	Ser
									65					75
Leu	Gly	Ser	Tyr	Ala	Ala	Leu	His	Gly	Glu	Phe	Tyr	Cys	Lys	Pro
									80					90
His	Phe	Gln	Gln	Leu	Phe	Lys	Ser	Lys	Gly	Asn	Tyr	Asp	Glu	Gly
									95					105
Phe	Gly	Arg	Lys	Gln	His	Lys	Glu	Leu	Trp	Ala	His	Lys	Glu	Val
									110					120
Asp	Pro	Gly	Thr	Lys	Thr	Ala								
									125					

<210> 13
 <211> 93
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 569989CD1

<400> 13
 Met Ile His Leu Gly His Ile Leu Phe Leu Leu Leu Pro Val
 1 5 10 15
 Ala Ala Ala Gln Thr Thr Pro Gly Glu Arg Ser Ser Leu Pro Ala
 20 25 30
 Phe Tyr Pro Gly Thr Ser Gly Ser Cys Ser Gly Cys Gly Ser Leu
 35 40 45
 Ser Leu Pro Leu Leu Ala Gly Leu Val Ala Ala Asp Ala Val Ala
 50 55 60
 Ser Leu Leu Ile Val Gly Ala Val Phe Leu Cys Ala Arg Pro Arg
 65 70 75
 Arg Ser Pro Ala Gln Glu Asp Gly Lys Val Tyr Ile Asn Met Pro
 80 85 90
 Gly Arg Gly

<210> 14
 <211> 225
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 2349263CD1

<400> 14
 Met Thr Ser Gln Pro Val Pro Asn Glu Thr Ile Ile Val Leu Pro
 1 5 10 15
 Ser Asn Val Ile Asn Phe Ser Gln Ala Glu Lys Pro Glu Pro Thr
 20 25 30
 Asn Gln Gly Gln Asp Ser Leu Lys Lys His Leu His Ala Glu Ile
 35 40 45
 Lys Val Ile Gly Thr Ile Gln Ile Leu Cys Gly Met Met Val Leu
 50 55 60
 Ser Leu Gly Ile Ile Leu Ala Ser Ala Ser Phe Ser Pro Asn Phe
 65 70 75
 Thr Gln Val Thr Ser Thr Leu Leu Asn Ser Ala Tyr Pro Phe Ile
 80 85 90
 Gly Pro Phe Phe Phe Ile Ile Ser Gly Ser Leu Ser Ile Ala Thr
 95 100 105
 Glu Lys Arg Leu Thr Lys Leu Leu Val His Ser Ser Leu Val Gly
 110 115 120
 Ser Ile Leu Ser Ala Leu Ser Ala Leu Val Gly Phe Ile Ile Leu
 125 130 135
 Ser Val Lys Gln Ala Thr Leu Asn Pro Ala Ser Leu Gln Cys Glu
 140 145 150
 Leu Asp Lys Asn Asn Ile Pro Thr Arg Ser Tyr Val Ser Tyr Phe
 155 160 165
 Tyr His Asp Ser Leu Tyr Thr Thr Asp Cys Tyr Thr Ala Lys Ala
 170 175 180
 Ser Leu Ala Gly Thr Leu Ser Leu Met Leu Ile Cys Thr Leu Leu

185	190	195
Glu Phe Cys Leu Ala Val Leu Thr Ala	Val Leu Arg Trp Lys Gln	
200	205	210
Ala Tyr Ser Asp Phe Pro Gly Val Ser	Val Leu Ala Gly Phe Thr	
215	220	225

<210> 15
<211> 547
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 2471716CD1

<400> 15		
Met Ser Glu Pro Pro Val Tyr Cys Asn Leu Val Asp Leu Arg Arg		
1 5 10 15		
Cys Pro Arg Ser Pro Pro Pro Gly Pro Ala Cys Pro Leu Leu Gln		
20 25 30		
Arg Leu Asp Ala Trp Glu Gln His Leu Asp Pro Asn Ser Gly Arg		
35 40 45		
Cys Phe Tyr Ile Asn Ser Leu Thr Gly Cys Lys Ser Trp Lys Pro		
50 55 60		
Pro Arg Arg Ser Arg Ser Glu Thr Asn Pro Gly Ser Met Glu Gly		
65 70 75		
Thr Gln Thr Leu Lys Arg Asn Asn Asp Val Leu Gln Pro Gln Ala		
80 85 90		
Lys Gly Phe Arg Ser Asp Thr Gly Thr Pro Glu Pro Leu Asp Pro		
95 100 105		
Gln Gly Ser Leu Ser Leu Ser Gln Arg Thr Ser Gln Leu Asp Pro		
110 115 120		
Pro Ala Leu Gln Ala Pro Arg Pro Leu Pro Gln Leu Leu Asp Asp		
125 130 135		
Pro His Glu Val Glu Lys Ser Gly Leu Leu Asn Met Thr Lys Ile		
140 145 150		
Ala Gln Gly Gly Arg Lys Leu Arg Lys Asn Trp Gly Pro Ser Trp		
155 160 165		
Val Val Leu Thr Gly Asn Ser Leu Val Phe Tyr Arg Glu Pro Pro		
170 175 180		
Pro Thr Ala Pro Ser Ser Gly Trp Gly Pro Ala Gly Ser Arg Pro		
185 190 195		
Glu Ser Ser Val Asp Leu Arg Gly Ala Ala Leu Ala His Gly Arg		
200 205 210		
His Leu Ser Ser Arg Arg Asn Val Leu His Ile Arg Thr Ile Pro		
215 220 225		
Gly His Glu Phe Leu Leu Gln Ser Asp His Glu Thr Glu Leu Arg		
230 235 240		
Ala Trp His Arg Ala Leu Arg Thr Val Ile Glu Arg Leu Asp Arg		
245 250 255		
Glu Asn Pro Leu Glu Leu Arg Leu Ser Gly Ser Gly Pro Ala Glu		
260 265 270		
Leu Ser Ala Gly Glu Asp Glu Glu Glu Glu Ser Glu Leu Val Ser		
275 280 285		
Lys Pro Leu Leu Arg Leu Ser Ser Arg Arg Ser Ser Ile Arg Gly		
290 295 300		
Pro Glu Gly Thr Glu Gln Asn Arg Val Arg Asn Lys Leu Lys Arg		
305 310 315		
Leu Ile Ala Lys Arg Pro Pro Leu Gln Ser Leu Gln Glu Arg Gly		
320 325 330		
Leu Leu Arg Asp Gln Val Phe Gly Cys Gln Leu Glu Ser Leu Cys		
335 340 345		

Gln Arg Glu Gly Asp Thr Val Pro Ser Phe Leu Arg Leu Cys Ile
 350 355 360
 Ala Ala Val Asp Lys Arg Gly Leu Asp Val Asp Gly Ile Tyr Arg
 365 370 375
 Val Ser Gly Asn Leu Ala Val Val Gln Lys Leu Arg Phe Leu Val
 380 385 390
 Asp Arg Glu Arg Ala Val Thr Ser Asp Gly Arg Tyr Val Phe Pro
 395 400 405
 Glu Gln Pro Gly Gln Glu Gly Arg Leu Asp Leu Asp Ser Thr Glu
 410 415 420
 Trp Asp Asp Ile His Val Val Thr Gly Ala Leu Lys Leu Phe Leu
 425 430 435
 Arg Glu Leu Pro Gln Pro Leu Val Pro Pro Leu Leu Leu Pro His
 440 445 450
 Phe Arg Ala Ala Leu Ala Leu Ser Glu Ser Glu Gln Cys Leu Ser
 455 460 465
 Gln Ile Gln Glu Leu Ile Gly Ser Met Pro Lys Pro Asn His Asp
 470 475 480
 Thr Leu Arg Tyr Leu Leu Glu His Leu Cys Arg Val Ile Ala His
 485 490 495
 Ser Asp Lys Asn Arg Met Thr Pro His Asn Leu Gly Ile Val Phe
 500 505 510
 Gly Pro Thr Leu Phe Arg Pro Glu Gln Glu Thr Ser Asp Pro Ala
 515 520 525
 Ala His Ala Leu Tyr Pro Gly Gln Leu Val Gln Leu Met Leu Thr
 530 535 540
 Asn Phe Thr Ser Leu Phe Pro
 545

<210> 16
 <211> 265
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 2726173CD1

<400> 16

Met Thr Val Asp Ser Ser Met Ser Ser Gly Tyr Cys Ser Leu Asp			
1	5	10	15
Glu Glu Leu Glu Asp Cys Phe Phe Thr Ala Lys Thr Thr Phe Phe			
20	25		30
Arg Asn Ala Gln Ser Lys His Leu Ser Lys Asn Val Cys Lys Pro			
35	40		45
Val Glu Glu Thr Gln Arg Pro Pro Thr Leu Gln Glu Ile Lys Gln			
50	55		60
Lys Ile Asp Ser Tyr Asn Thr Arg Glu Lys Asn Cys Leu Gly Met			
65	70		75
Lys Leu Ser Glu Asp Gly Thr Tyr Thr Gly Phe Ile Lys Val His			
80	85		90
Leu Lys Leu Arg Arg Pro Val Thr Val Pro Ala Gly Ile Arg Pro			
95	100		105
Gln Ser Ile Tyr Asp Ala Ile Lys Glu Val Asn Leu Ala Ala Thr			
110	115		120
Thr Asp Lys Arg Thr Ser Phe Tyr Leu Pro Leu Asp Ala Ile Lys			
125	130		135
Gln Leu His Ile Ser Ser Thr Thr Thr Val Ser Glu Val Ile Gln			
140	145		150
Gly Leu Leu Lys Lys Phe Met Val Val Asp Asn Pro Gln Lys Phe			
155	160		165
Ala Leu Phe Lys Arg Ile His Lys Asp Gly Gln Val Leu Phe Gln			

Lys	Leu	Ser	Ile	Ala	Asp	Arg	Pro	Leu	Tyr	Leu	Arg	Leu	Leu	Ala
170				185					190					195
Gly	Pro	Asp	Thr	Glu	Val	Leu	Asn	Phe	Val	Leu	Lys	Glu	Asn	Glu
185				200					205					210
Thr	Gly	Glu	Val	Glu	Trp	Asp	Ala	Phe	Ser	Ile	Pro	Glu	Leu	Gln
200				215					220					225
Asn	Phe	Leu	Thr	Ile	Leu	Glu	Lys	Glu	Glu	Gln	Asp	Lys	Ile	Gln
215				230					235					240
Gln	Val	Gln	Lys	Lys	Tyr	Asp	Lys	Phe	Arg	Gln	Lys	Leu	Glu	Glu
230				245					250					255
Ala	Leu	Arg	Glu	Ser	Gln	Gly	Lys	Pro	Gly					
245				260					265					

<210> 17
<211> 394
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 3507924CD1

<400> 17

Met	Phe	Cys	Pro	Leu	Lys	Leu	Ile	Leu	Leu	Pro	Val	Leu	Leu	Asp
1				5					10					15
Tyr	Ser	Leu	Gly	Leu	Asn	Asp	Leu	Asn	Val	Ser	Pro	Pro	Glu	Leu
				20					25					30
Thr	Val	His	Val	Gly	Asp	Ser	Ala	Leu	Met	Gly	Cys	Val	Phe	Gln
				35					40					45
Ser	Thr	Glu	Asp	Lys	Cys	Ile	Phe	Lys	Ile	Asp	Trp	Thr	Leu	Ser
				50					55					60

Pro	Gly	Glu	His	Ala	Lys	Asp	Glu	Tyr	Val	Leu	Tyr	Tyr	Tyr	Ser
				65					70					75
Asn	Leu	Ser	Val	Pro	Ile	Gly	Arg	Phe	Gln	Asn	Arg	Val	His	Leu
				80					85					90
Met	Gly	Asp	Ile	Leu	Cys	Asn	Asp	Gly	Ser	Leu	Leu	Leu	Gln	Asp
				95					100					105
Val	Gln	Glu	Ala	Asp	Gln	Gly	Thr	Tyr	Ile	Cys	Glu	Ile	Arg	Leu
				110					115					120
Lys	Gly	Glu	Ser	Gln	Val	Phe	Lys	Lys	Ala	Val	Val	Leu	His	Val
				125					130					135
Leu	Pro	Glu	Glu	Pro	Lys	Glu	Leu	Met	Val	His	Val	Gly	Gly	Leu
				140					145					150
Ile	Gln	Met	Gly	Cys	Val	Phe	Gln	Ser	Thr	Glu	Val	Lys	His	Val
				155					160					165
Thr	Lys	Val	Glu	Trp	Ile	Phe	Ser	Gly	Arg	Arg	Ala	Lys	Glu	Glu
				170					175					180
Ile	Val	Phe	Arg	Tyr	Tyr	His	Lys	Leu	Arg	Met	Ser	Val	Glu	Tyr
				185					190					195
Ser	Gln	Ser	Trp	Gly	His	Phe	Gln	Asn	Arg	Val	Asn	Leu	Val	Gly
				200					205					210
Asp	Ile	Phe	Arg	Asn	Asp	Gly	Ser	Ile	Met	Leu	Gln	Gly	Val	Arg
				215					220					225
Glu	Ser	Asp	Gly	Gly	Asn	Tyr	Thr	Cys	Ser	Ile	His	Leu	Gly	Asn
				230					235					240
Leu	Val	Phe	Lys	Lys	Thr	Ile	Val	Leu	His	Val	Ser	Pro	Glu	Glu
				245					250					255
Pro	Arg	Thr	Leu	Val	Thr	Pro	Ala	Ala	Leu	Arg	Pro	Leu	Val	Leu
				260					265					270
Gly	Gly	Asn	Gln	Leu	Val	Ile	Ile	Val	Gly	Ile	Val	Cys	Ala	Thr

	275	280	285
Ile Leu Leu Leu	Pro Val Leu Ile Leu	Ile Val Lys Lys Thr	Cys
290	295	300	
Gly Asn Lys Ser	Ser Val Asn Ser Thr	Val Leu Val Lys Asn	Thr
305	310	315	
Lys Lys Thr Asn	Pro Glu Ile Lys Glu	Lys Pro Cys His Phe	Glu
320	325	330	
Arg Cys Glu Gly	Glu Lys His Ile Tyr	Ser Pro Ile Ile Val	Arg
335	340	345	
Glu Val Ile Glu	Glu Glu Glu Pro Ser	Glu Lys Ser Glu Ala	Thr
350	355	360	
Tyr Met Thr Met	His Pro Val Trp Pro	Ser Leu Arg Ser Asp	Arg
365	370	375	
Asn Asn Ser Leu	Glu Lys Lys Ser Gly	Gly Gly Met Pro Lys	Thr
380	385	390	
Gln Gln Ala Phe			

This Page Blank (uspto)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, C12N 1/00, A61K 38/17, C07K 16/18, C12Q 1/68		A3	(11) International Publication Number: WO 00/29574
			(43) International Publication Date: 25 May 2000 (25.05.00)
(21) International Application Number: PCT/US99/26234		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 4 November 1999 (04.11.99)			
(30) Priority Data: 09/195,292 18 November 1998 (18.11.98) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/195,292 (CIP) Filed on 18 November 1998 (18.11.98)			
(71) Applicant (<i>for all designated States except US</i>): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US)		Published <i>With international search report.</i>	
(72) Inventors; and			
(75) Inventors/Applicants (<i>for US only</i>): WALKER, Michael, G. [CA/US]; Unit 80, 1050 Borregas Avenue, Sunnyvale, CA 94089 (US). VOLKMUTH, Wayne [US/US]; 783 Roble Avenue #1, Menlo Park, CA 94025 (US). KLINGLER, Tod, M. [US/US]; 28 Dover Court, San Carlos, CA 94070 (US).			
(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).			
(54) Title: INFLAMMATION-ASSOCIATED GENES			
(57) Abstract			
<p>The invention provides novel inflammation-associated genes and polypeptides encoded by those genes. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing diseases associated with inflammation.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/26234

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C12N1/00 A61K38/17 C07K16/18
C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 16639 A (PLOWMAN GREGORY D ; SCHLESSINGER JOSEPH (US); SUGEN INC (US); UNIV) 23 April 1998 (1998-04-23) abstract; claims 1-20; figure 1 see SEQ ID NO: 2 (p. 36/37) page 1 -page 28 --- DATABASE EMEST6 [Online] EMBL, Heidelberg, Germany AC/ID AI083668, 18 August 1998 (1998-08-18) NCI-CGAP: "Homo sapiens cDNA clone IMAGE: 1671300" XP002134299 abstract --- -/-	1-3,5-7, 9-12
X		1,2,5,6, 9

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

29 March 2000

Date of mailing of the international search report

05.07.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Oderwald, H

INTERNATIONAL SEARCH REPORT

Internal Application No

US 99/26234

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 35372 A (HUMAN GENOME SCIENCES INC ;GENTZ REINER L (US); FLEISCHMANN ROBERT) 28 December 1995 (1995-12-28) the whole document ---	1,3
X	TING A. T. ET AL.: "Interaction between lck and syk family tyrosine kinases in Fc γ receptor-initiated activation of natural killer cells" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 27, 7 July 1995 (1995-07-07), pages 16415-16421, XP002134296 the whole document ---	1,3
X	INAGAKI H. ET AL.: "Increased susceptibility to primary infection with Listeria monocytogenes in germfree mice may be due to lack of accumulation of l-selectin+ and CD44+ T cells in sites of inflammation" INFECTION AND IMMUNITY, vol. 64, no. 8, August 1996 (1996-08), pages 3280-3287, XP002134297 the whole document ---	1,3
X	PANDEY A. ET AL.: "Characterization of a novel Src-like adapter protein that associates with the Eck receptor tyrosine kinase" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 33, 18 August 1995 (1995-08-18), pages 19201-19204, XP002134298 the whole document ---	1,3
X	J C WU ET AL: "Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, 1 January 1994 (1994-01-01), pages 674-678, XP002080082 ISSN: 0027-8424 the whole document ---	1,3
		-/-

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/26234

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>WO 99 47655 A (SCHMITT ARMIN ;SPECHT THOMAS (DE); DAHL EDGAR (DE); HINZMANN BERND) 23 September 1999 (1999-09-23) abstract; claims 1-36; figures 1-3; examples 1,2 page 35 see SEQ ID NO: 31 and 108 (pp.132-134 and 187 -----</p>	1-12

INTERNATIONAL SEARCH REPORT

In. ational application No.
PCT/US 99/26234

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
- Although claims 10-12 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheets

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-12 all partially

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-12 {all partially}

A polynucleotide comprising a gene that is co-expressed with one or more known inflammation genes in a plurality of biological samples, wherein each known inflammation gene is selected from the group consisting of CD16, L-selectin, SRC-like adapter protein, IP-30, superoxidase homoenzyme subunits, alpha-1-antitrypsin, Clq-A, 5-lipoxygenase activating protein and SRC family tyrosine kinase, said polynucleotide comprising SEQ ID NO:1, a polypeptide encoded by said polynucleotide comprising SEQ ID NO: 12, an expression vector, a host cell, a pharmaceutical composition, an antibody, a method of diagnosing a disease, methods of treating or preventing a disease comprising said polynucleotide and polypeptide.

2. Claims: 1-12 {all partially}

same as invention 1 but comprising polynucleotide SEQ ID NO: 2 and polypeptide SEQ ID NO: 13.

3. Claims: 1-12 {all partially}

same as invention 1 but comprising polynucleotide SEQ ID NO: 3.

4. Claims: 1-12 {all partially}

same as invention 1 but comprising polynucleotide SEQ ID NO: 4.

5. Claims: 1-12 {all partially}

same as invention 1 but comprising polynucleotide SEQ ID NO: 5.

6. Claims: 1-12 {all partially}

same as invention 1 but comprising polynucleotide SEQ ID NO: 6 and polypeptide SEQ ID NO: 14.

7. Claims: 1-12 {all partially}

same as invention 1 but comprising polynucleotide SEQ ID NO: 7 and polypeptide SEQ ID NO: 15.

8. Claims: 1-12 {all partially}

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

same as invention 1 but comprising polynucleotide SEQ ID NO: 8 and polypeptide SEQ ID NO: 16.

9. Claims: 1-12 {all partially}

same as invention 1 but comprising polynucleotide SEQ ID NO: 9.

10. Claims: 1-12 {all partially}

same as invention 1 but comprising polynucleotide SEQ ID NO: 10.

11. Claims: 1-12 {all partially}

same as invention 1 but comprising polynucleotide SEQ ID NO: 11 and polypeptide SEQ ID NO: 17.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/26234

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9816639	A 23-04-1998	AU 4654097 A	EP 0931146 A		11-05-1998 28-07-1999
WO 9535372	A 28-12-1995	US 5696076 A	AU 2901495 A	EP 0777729 A	09-12-1997 15-01-1996 11-06-1997
		JP 10501969 T	ZA 9505186 A		24-02-1998 23-12-1996
WO 9947655	A 23-09-1999	DE 19813835 A			23-09-1999

This Page Blank (uspto)